White Book - MGB Antimicrobial Dosing June 2023 (2024)

Table of Contents
Acyclovir IV: disseminated HSV, HSV encephalitis, visceral zoster, VZV/HSV retinal necrosis Acyclovir IV: localized HSV: genital, perirectal, mucosal, or cutaneous HSV Acyclovir PO: HSV labialis, mild genital/perirectal HSV Acyclovir PO: herpes zoster Acyclovir PO: prophylaxis/suppression Acyclovir IV: prophylaxis/suppression Albendazole PO: ancylostomiasis, necatoriasis, cutaneous larva migrans, or enterobiasis Albendazole PO: echinococcosis or neurocysticercosis Amikacin ✱ID✱ Amoxicillin PO Amoxicillin PO: procedure prophylaxis for infective endocarditis, dental procedures Amoxicillin-clavulanate PO Amoxicillin-clavulanate PO XR: community acquired pneumonia, acute bacterial sinusitis Liposomal Amphotericin B IV: candidemia, febrile neutropenia, cryptococcosis ✱ID✱ Liposomal Amphotericin B IV: aspergillosis, mucormycosis ✱ID✱ Liposomal Amphotericin B Inhaled: prophylaxis for Aspergillus ✱ID✱ Amphotericin B lipid complex (Abelcet) Inhaled: prophylaxis for Aspergillus ✱ID✱ Amphotericin B deoxycholate IV ✱ID✱ Ampicillin IV: bacteremia and other systemic infections Ampicillin IV: bacterial meningitis, endocarditis, or Listeria Ampicillin PO: Mild GI, GU, and upper respiratory tract infections Ampicillin-sulbactam IV: Acinetobacter baumannii, Enterococcal endocarditis Ampicillin-sulbactam IV: Skin and soft tissue infections, intra-abdominal infections, pelvic inflammatory disease Artemether-lumefantrine PO: P. falciparum malaria for patients weighing >35kg Atovaquone PO: Pneumocystis jirovecii pneumonia prophylaxis Atovaquone PO: Pneumocystis jirovecii pneumonia treatment or prophylaxis, babesiosis treatment Atovaquone PO: toxoplasmosis treatment Atovaquone-proguanil PO: P. falciparum malaria treatment Atovaquone-proguanil PO: P. falciparum malaria prophylaxis Azithromycin PO/IV: bacterial sinusitis, community acquired pneumonia, skin and soft tissue infections, pertussis Azithromycin PO: MAC prophylaxis Aztreonam IV ✱ID✱ Baloxavir PO ✱ID✱ Bedaquiline PO Bezlotoxumab IV: CDI recurrence ✱ID✱ Cefaclor PO Cefadroxil PO Cefazolin IV Cefdinir PO Cefepime IV: febrile neutropenia, pneumonia, cystic fibrosis, non-UTI Pseudomonas aeruginosa Cefepime IV: other infections Cefepime IV: alternative dosing; may replace 2gm Q8H and 2gm Q12H dosing; EXCEPT for febrile neutropenia and CNS infections Cefiderocol IV ✱ID✱ Cefixime PO Cefixime PO: uncomplicated gonorrhea Cefotaxime IV Cefotetan IV Cefoxitin IV Cefoxitin IV: nontuberculous mycobacterial infections Cefpodoxime PO Cefprozil PO: acute bacterial exacerbation of chronic bronchitis, uncomplicated skin and soft tissue infection Cefprozil PO: pharyngitis, tonsillitis Ceftaroline fosamil IV: community acquired pneumonia, skin and soft tissue infections ✱ID✱ Ceftaroline fosamil IV: MRSA bacteremia, MRSA pneumonia, severe MRSA infections ✱ID✱ Ceftazidime IV: febrile neutropenia, pneumonia, bacteremia, sepsis Ceftazidime IV: UTI, if urosepsis follow above dosing recommendations Ceftazidime-avibactam IV ✱ID✱ Ceftolozane-tazobactam IV: complicated urinary tract infections and complicated intra-abdominal infections ✱ID✱ Ceftolozane-tazobactam IV: ventilator-associated pneumonia or MDRO pathogens ✱ID✱ Ceftriaxone IV: bloodstream infections, bone or joint infections, pneumonia, intra-abdominal infections, Lyme disease Ceftriaxone IV: urinary tract infections, skin and soft tissue infections, pneumonia, intra-abdominal infections, SBP prophylaxis Ceftriaxone IV: bacterial meningitis or Enterococcal endocarditis Ceftriaxone IM: gonorrhea Cefuroxime IV Cefuroxime PO Cephalexin PO Chloramphenicol IV Chloroquine Phosphate PO: malaria treatment Chloroquine Phosphate PO: malaria prophylaxis Cidofovir IV ✱ID✱ Cidofovir IV: BK virus nephropathy ✱ID✱ Ciprofloxacin IV Ciprofloxacin PO Ciprofloxacin PO: Spontaneous Bacterial Peritonitis Prophylaxis Clarithromycin PO Clindamycin PO: mild-to-moderate infections Clindamycin PO: complicated skin and soft tissue infections, pneumonia, or bone & joint infections due to MRSA Clindamycin Phosphate IV Clofazimine PO: nontuberculous mycobacterial infections Colistimethate IV ✱ID✱ Cycloserine PO: tuberculosis ✱ID✱ Dalbavancin IV: MRSA skin and soft tissue infection ✱ID✱ Dalbavancin IV: osteomyelitis ✱ID✱ Dapsone PO: Pneumocystis jirovecii pneumonia treatment or prophylaxis Dapsone PO: Pneumocystis jirovecii pneumonia prophlaxis alternate dosing Daptomycin IV: MRSA bacteremia or endocarditis ✱ID✱ Daptomycin IV: VRE bacteremia or endocarditis ✱ID✱ Daptomycin IV: Skin and soft tissue infections ✱ID✱ Delafloxacin PO: pneumonia, skin and soft tissue infections ✱ID✱ Delafloxacin IV: pneumonia, skin and soft tissue infections ✱ID✱ Dicloxacillin Sodium PO Doxycycline PO/IV Eravacycline IV ✱ID✱ Ertapenem IV ✱ID✱ Erythromycin Lactobionate IV Erythromycin Lactobionate IV: GI motility Erythromycin PO tablets Erythromycin Ethylsuccinate PO solution Ethambutol PO: tuberculosis Ethionamide PO: tuberculosis Famciclovir PO: herpes zoster Famciclovir PO: HSV-recurrent genital herpes Famciclovir PO: Suppression for HSV-recurrent orolabial and genital HSV infection in HIV-infected patients Famciclovir PO: MGH-only – HSV/VZV prophylaxis in low CMV risk kidney, liver, and heart transplants Fidaxomicin PO: Clostridioides difficile infection ✱ID✱ Fidaxomicin PO: Pulse dosing for recurrent Clostridioides difficile infection ✱ID✱ Fluconazole PO/IV: invasive candidiasis treatment Fluconazole PO/IV: invasive candidiasis treatment, alternative weight-based treatment for extremes in body weight Fluconazole PO: vagin*l candidiasis Fluconazole PO/IV: thrush/oropharyngeal candidiasis Fluconazole PO/IV: prophylaxis dosing Flucytosine PO: cryptococcal meningitis Foscarnet IV: CMV induction, HHV-6 ✱ID✱ Foscarnet IV: CMV maintenance ✱ID✱ Foscarnet IV: HSV-1 or -2 infection ✱ID✱ Fosfomycin PO: uncomplicated UTI Fosfomycin PO: complicated UTI, prostatitis Ganciclovir IV: CMV, induction ✱ID✱ Ganciclovir IV: CMV, maintenance or prophylaxis ✱ID✱ Gentamicin IV Griseofulvin Microsize: tinea barbae, tinea capitis, tinea corporis, tinea cruris Griseofulvin Microsize: tinea pedis, tinea unguium Griseofulvin Ultramicrosize: tinea barbae, tinea capitis, tinea corporis, tinea cruris Griseofulvin Ultramicrosize: tinea pedis, tinea unguium Hydroxychloroquine PO: malaria treatment Hydroxychloroquine PO: malaria prophylaxis Imipenem-cilastatin IV: most bacterial infections ✱ID✱ Imipenem-cilastatin IV: most mycobacterial infections ✱ID✱ Imipenem-cilastatin IV: Bacterial or mycobacterial infections with intermediate susceptibility to imipenem ✱ID✱ Imipenem-cilastatin and relebactam IV: most bacterial infections ✱ID✱ Isavuconazonium sulfate PO/IV: invasive aspergillosis, mucormycosis ✱ID✱ Isoniazid PO: tuberculosis Itraconazole PO suspension: aspergillosis, cryptococcosis, febrile neutropenia, histoplasmosis Ivermectin PO: Strongyloidiasis, cutaneous larva migrans Lefamulin PO ✱ID✱ Lefamulin IV ✱ID✱ Letermovir PO/IV: CMV prophylaxis in patients post-allogeneic hematopoietic stem cell transplant ✱ID✱ Levofloxacin PO/IV: nosocomial and community acquired pneumonia, complicated skin and soft tissue infections, MDR tuberculosis Levofloxacin PO/IV: sinusitis, uncomplicated skin and soft tissue infections, UTI Linezolid PO/IV ✱ID✱ Linezolid PO/IV: mycobacterial infections ✱ID✱ Maribavir PO: CMV treatment ✱ID✱ Mebendazole PO: Ascariasis, trichuriasis Mefloquine PO: Malaria treatment Mefloquine PO: Malaria prophylaxis Meropenem IV: febrile neutropenia, pneumonia, bacteremia, sepsis, UTIs, gynecologic infections, intra-abdominal infections, mycobacterial infections ✱ID✱ Meropenem IV: bacterial meningitis, cystic fibrosis, infection with confirmed elevated MIC to meropenem ✱ID✱ Meropenem IV: alternative dosing; may replace 1gm Q8H dosing; EXCEPT for febrile neutropenia and CNS infections ✱ID✱ Meropenem-vaborbactam IV ✱ID✱ Metronidazole PO/IV: most indications Metronidazole PO/IV: C. difficile, CNS anaerobic infections Micafungin IV: febrile neutropenia, candidemia, invasive candidiasis, Candida peritonitis, or abscesses ✱ID✱ Micafungin IV: esophageal candidiasis, refractory aspergillosis, consider for fungal endocarditis ✱ID✱ Minocycline HCl PO/IV: most indications Moxifloxacin PO/IV ✱ID✱ Nafcillin IV: MSSA bacteremia, endocarditis, meningitis, and pneumonia Nitazoxanide PO: cryptosporidiosis, giardiasis Nitrofurantoin PO (Macrobid SR): uncomplicated female or male UTI Nitrofurantoin PO (Macrobid IR): uncomplicated female or male UTI Nystatin PO: intestinal infections Omadacycline IV ✱ID✱ Omadacycline PO ✱ID✱ Oritavancin IV: MRSA skin and soft tissue infection ✱ID✱ Oseltamivir Phosphate PO: influenza treatment Oseltamivir Phosphate PO: influenza treatment (ONLY FOR SITES THAT DO NOT STOCK 30mg CAPSULES) Oseltamivir Phosphate PO: influenza prophylaxis Oseltamivir Phosphate PO: influenza prophylaxis (ONLY FOR SITES THAT DO NOT STOCK 30mg CAPSULES) Oxacillin Sodium IV: MSSA bacteremia, endocarditis, pneumonia, meningitis Paromomycin PO: intestinal amebiasis Penicillin G IV: endocarditis, bacteremia, neurosyphilis, pneumonia, sepsis Penicillin G IV 24H continuous infusion: endocarditis, bacteremia, neurosyphilis, pneumonia, sepsis Penicillin G IV Penicillin V PO (Pen-VK, Veetids): pneumococcal respiratory tract infection, otitis media, pharyngitis, gingivitis, staphylococcal skin and soft tissue infection Penicillin V PO (Pen-VK, Veetids): prophylaxis for rheumatic fever, chorea, or meningococcal disease post-eculizumab Penicillin G Benzathine IM (Bicillin L-A) Penicillin G Procaine IM (Wycillin, Bicillin C-R): neurosyphilis Penicillin G Procaine IM (Wycillin, Bicillin C-R): other infections Pentamidine IV/IM: Pneumocystis jirovecii pneumonia treatment Pentamidine IV/IM/inhalation: Pneumocystis jirovecii pneumonia prophylaxis Peramivir IV: influenza, acute, uncomplicated Piperacillin-tazobactam IV: nosocomial pneumonia, febrile neutropenia, cystic fibrosis exacerbations, endometritis Piperacillin-tazobactam IV: appendicitis, peritonitis, pelvic inflammatory disease, complicated skin and soft tissue infections Piperacillin-tazobactam IV: site-specific extended infusion dosing Plazomicin IV ✱ID✱ Polymyxin B Sulfate IV ✱ID✱ Posaconazole PO: prophylaxis or treatment ✱ID✱ Posaconazole IV: prophylaxis or treatment ✱ID✱ Posaconazole PO oral suspension: treatment ✱ID✱ Posaconazole PO oral suspension: prophylaxis ✱ID✱ Primaquine Phosphate PO: malaria Pyrantel PO Pyrazinamide PO: tuberculosis Pyrimethamine PO: toxoplasmosis treatment ✱ID✱ Pyrimethamine PO: toxoplasmosis or Pneumocystis jirovecii pneumonia prophylaxis ✱ID✱ Quinine PO: malaria, babesiosis treatment Quinupristin-dalfopristin IV: complicated skin infections due to MRSA ✱ID✱ Quinupristin-dalfopristin IV: bacteremia due to vancomycin-resistant E. faecium ✱ID✱ Remdesivir IV: COVID-19 Rifabutin PO: treatment for tuberculosis or disseminated MAC Rifampin PO/IV: tuberculosis ✱ID✱ Rifampin PO/IV: prosthetic joint infections ✱ID✱ Rifampin PO/IV: prosthetic valve endocarditis ✱ID✱ Rifapentine PO: tuberculosis, intensive phase ✱ID✱ Rifapentine PO: tuberculosis, continuation phase ✱ID✱ Rifaximin PO: recurrent Clostridioides difficile infection Rifaximin PO: hepatic encephalopathy Rifaximin PO: traveler's diarrhea Sulfadiazine PO: Toxoplasma gondii encephalitis, acute infection Sulfadiazine PO: Toxoplasma gondii encephalitis, chronic maintenance therapy Streptomycin IM/IV Streptomycin IM/IV: gentamicin-resistant enterococcal endocarditis dosing Tedizolid PO/IV: MRSA skin and soft tissue infection ✱ID✱ Telavancin IV: Serious Gram-positive infections refractory to first-line agents ✱ID✱ Terbinafine PO: Fusarium, cutaneous and lymphocutaneous Sporotrichosis Terbinafine PO: onychomycosis Tetracycline PO Tigecycline IV ✱ID✱ Tigecycline IV: nontuberculous mycobacterial infections ✱ID✱ Tinidazole PO: amebiasis, bacterial vaginosis Tinidazole PO: giardiasis, trichom*oniasis Tobramycin IV Trimethoprim-sulfamethoxazole PO/IV: Pneumocystis jirovecii pneumonia, severe Nocardia infections, treatment dosing Trimethoprim-sulfamethoxazole PO/IV: Treatment of Stenotrophom*onas maltophilia or other systemic infections Trimethoprim-sulfamethoxazole PO: urinary tract infections Trimethoprim-sulfamethoxazole PO: uncomplicated skin and soft tissue infections Trimethoprim-sulfamethoxazole PO: lung transplant or HIV-infected Pneumocystis jirovecii pneumonia prophylaxis Trimethoprim-sulfamethoxazole PO: renal transplant Pneumocystis jirovecii pneumonia prophylaxis Valacyclovir PO: Zoster/HSV treatment Valacyclovir PO: prophylaxis/suppression, including lung transplant prophylaxis Valacyclovir PO: Renal Transplant prophylaxis Valganciclovir PO: Renal transplant prophylaxis Valganciclovir PO: maintenance/suppression/prophylaxis Valganciclovir PO: CMV treatment Vancomycin IV: systemic infections Vancomycin PO: Clostridioides difficile treatment ONLY Vancomycin PO: Clostridioides difficile prophylaxis ONLY Voriconazole PO ✱ID✱ Voriconazole IV ✱ID✱ Zanamivir Inhalation: influenza treatment ✱ID✱ FAQs

Adapted from MGB guidelines, June 2023. Please refer to the original source for definitive guidance.
✱ID✱ indicates that Infectious Disease approval is required, unless otherwise noted by the individual hospital protocol.
Renal dosing adjustments should be calculated by the co*ckcroft-Gault Equation, not estimated GFR, unless otherwise noted.

  • ACYCLOVIR Sitavig, Zovirax
  • Acyclovir IV: disseminated HSV, HSV encephalitis, visceral zoster, VZV/HSV retinal necrosis

    CrCl ≥5010mg/kgQ8H
    26–4910mg/kgQ12H
    10–2510mg/kgQ24H
    <105mg/kgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    Maintain adequate hydration; BMI<25: use actual body weight; BMI≥25: use adjusted bodyweight; Discuss doses ≥1,000mg with ID; On dialysis days give post-HD

    ACYCLOVIR [#grey] | Sitavig, Zovirax
  • Acyclovir IV: localized HSV: genital, perirectal, mucosal, or cutaneous HSV

    CrCl ≥505mg/kgQ8H
    26–495mg/kgQ12H
    10–255mg/kgQ24H
    <102.5mg/kgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    Maintain adequate hydration; BMI<25: use actual body weight; BMI≥25: use adjusted bodyweight; Discuss doses ≥1,000mg with ID; On dialysis days give post-HD

    ACYCLOVIR [#grey] | Sitavig, Zovirax
  • Acyclovir PO: HSV labialis, mild genital/perirectal HSV

    CrCl ≥25400mgQ8H
    10–25400mgQ12H
    <10
    Hemodialysis
    Peritoneal dialysis600–800mgQ24H
    CVVHNO DATA
    ACYCLOVIR [#grey] | Sitavig, Zovirax
  • Acyclovir PO: herpes zoster

    CrCl ≥25800mg5x/day
    10–25800mgQ8H
    <10800mgQ12H
    Hemodialysis
    Peritoneal dialysisNO DATA
    CVVHNO DATA
    ACYCLOVIR [#grey] | Sitavig, Zovirax
  • Acyclovir PO: prophylaxis/suppression

    CrCl ≥25400mgQ8H–Q12H
    10–25400mgQ12H
    <10200–400mgQ12H
    Hemodialysis
    Peritoneal dialysisNO DATA
    CVVHNO DATA
    ACYCLOVIR [#grey] | Sitavig, Zovirax
  • Acyclovir IV: prophylaxis/suppression

    CrCl ≥50200mgQ8H–Q12H
    26–49200mgQ12H
    10–25200mgQ24H
    <10100mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH200mgQ24H
    ACYCLOVIR [#grey] | Sitavig, Zovirax
  • ALBENDAZOLE Albenza
  • Albendazole PO: ancylostomiasis, necatoriasis, cutaneous larva migrans, or enterobiasis

    All CrCl400mg1x or Q24H
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA
    ALBENDAZOLE [#grey] | Albenza
  • Albendazole PO: echinococcosis or neurocysticercosis

    All CrCl400mgQ12H
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    If <60kg: 15mg/kg/day divided into 2 doses, max 400 mg/dose

    ALBENDAZOLE [#grey] | Albenza
  • AMIKACIN Amikin
  • Amikacin ✱ID✱

    Please refer to Site-Specific Aminoglycoside Dosing Guidelines, when available.

    Please contact pharmacy department for help with monitoring serum concentrations and dosage adjustments

    AMIKACIN [#grey] | Amikin
  • AMOXICILLIN Amoxil, Trimox, Moxatag
  • Amoxicillin PO

    CrCl >30500–1000mgQ8H–Q12H
    10–30500–1000mgQ12H
    <10500mgQ24H
    Hemodialysis
    Peritoneal dialysis250mgQ12H
    CVVHNO DATA

    On dialysis days give post-HD

    AMOXICILLIN [#grey] | Amoxil, Trimox, Moxatag
  • Amoxicillin PO: procedure prophylaxis for infective endocarditis, dental procedures

    All CrCl2000mgx1
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Administer 30-60 minutes prior to procedure (use of IE Abx prophylaxis for Dental procedures limited to: pts with prosthetic valve, h/o IE, CHD, heart transplant recipients)

    AMOXICILLIN [#grey] | Amoxil, Trimox, Moxatag
  • AMOXICILLIN-CLAVULANATE Augmentin ER, Augmentin XR
  • Amoxicillin-clavulanate PO

    CrCl >30500–875mgQ8H–Q12H
    10–30500mgQ12H
    <10500mgQ24H
    Hemodialysis
    Peritoneal dialysis250mgQ12H
    CVVHNO DATA

    On dialysis days give post-HD; Some patients may require higher dosing despite renal function; Dosing based on amoxicillin component

    AMOXICILLIN-CLAVULANATE [#grey] | Augmentin ER, Augmentin XR
  • Amoxicillin-clavulanate PO XR: community acquired pneumonia, acute bacterial sinusitis

    CrCl ≥302gmQ12H
    <30AVOID

    Dosing based on amoxicillin component

    AMOXICILLIN-CLAVULANATE [#grey] | Augmentin ER, Augmentin XR
  • AMPHOTERICIN B AmphoB, AmBisome, Fungizone, Amphocin
  • Liposomal Amphotericin B IV: candidemia, febrile neutropenia, cryptococcosis ✱ID✱

    All CrCl3–5mg/kgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Infuse over 2–4 hours; On dialysis days give post-HD

    AMPHOTERICIN B [#grey] | AmphoB, AmBisome, Fungizone, Amphocin
  • Liposomal Amphotericin B IV: aspergillosis, mucormycosis ✱ID✱

    All CrCl5mg/kgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Infuse over 2–4 hours; On dialysis days give post-HD

    AMPHOTERICIN B [#grey] | AmphoB, AmBisome, Fungizone, Amphocin
  • Liposomal Amphotericin B Inhaled: prophylaxis for Aspergillus ✱ID✱

    All CrCl25mgTIW
    Hemodialysis
    Peritoneal dialysis
    CVVH
    AMPHOTERICIN B [#grey] | AmphoB, AmBisome, Fungizone, Amphocin
  • Amphotericin B lipid complex (Abelcet) Inhaled: prophylaxis for Aspergillus ✱ID✱

    All CrCl50mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Adjustments per transplant team

    AMPHOTERICIN B [#grey] | AmphoB, AmBisome, Fungizone, Amphocin
  • AMPHOTERICIN B DEOXYCHOLATE AmphoB, AmBisome, Fungizone, Amphocin
  • Amphotericin B deoxycholate IV ✱ID✱

    All CrCl0.25–1.5mg/kgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    May administer as continuous infusion over 24 hours; On dialysis days give post-HD. Due to high toxicity associated with the systemic use of this agent, this formulation is not recommended

    AMPHOTERICIN B DEOXYCHOLATE [#grey] | AmphoB, AmBisome, Fungizone, Amphocin
  • AMPICILLIN
  • Ampicillin IV: bacteremia and other systemic infections

    CrCl >502gmQ6H
    10–502gmQ8H–Q12H
    <102gmQ12H
    Hemodialysis2gmQ8H–Q12H
    Peritoneal dialysis2gmQ12H
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    AMPICILLIN [#grey]
  • Ampicillin IV: bacterial meningitis, endocarditis, or Listeria

    CrCl >502gmQ4H
    10–502gmQ6H–Q8H
    <102gmQ12H
    Hemodialysis2gmQ8H–Q12H
    Peritoneal dialysis2gmQ12H
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    AMPICILLIN [#grey]
  • Ampicillin PO: Mild GI, GU, and upper respiratory tract infections

    CrCl >50250-500mgQ6H
    10–50250-500mgQ6H–Q12H
    <10250-500mgQ12H–Q24H
    Hemodialysis250-500mgPost-HD
    Peritoneal dialysis250mgQ12H
    CVVHNO DATA

    Oral dosing not recommended in hospitalized patients

    AMPICILLIN [#grey]
  • AMPICILLIN-SULBACTAM Unasyn ADD-Vantage, amp-sulbactam
  • Ampicillin-sulbactam IV: Acinetobacter baumannii, Enterococcal endocarditis

    CrCl >303gm (2gm/1gm)Q4H–Q6H
    15–303gm (2gm/1gm)Q6H–Q8H
    <153gm (2gm/1gm)Q8H–Q12H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    Higher doses may be considered in certain MDR infections per IDSA guidelines. Discuss with ID Pharmacy or ID for dosing recommendations.

    AMPICILLIN-SULBACTAM [#grey] | Unasyn ADD-Vantage, amp-sulbactam
  • Ampicillin-sulbactam IV: Skin and soft tissue infections, intra-abdominal infections, pelvic inflammatory disease

    CrCl >303gm (2gm/1gm)Q6H
    15–303gm (2gm/1gm)Q8H-12H
    <153gm (2gm/1gm)Q12H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    AMPICILLIN-SULBACTAM [#grey] | Unasyn ADD-Vantage, amp-sulbactam
  • ARTEMETHER-LUMEFANTRINE Coartem
  • Artemether-lumefantrine PO: P. falciparum malaria for patients weighing >35kg

    All CrCl, weight >35kg80mg/480mg✱Q12H x 3 days
    All CrCl, weight 25–35kg60mg/360mg✱Q12H x 3 days
    HemodialysisSee above dosing based on weight
    Peritoneal dialysisSee above dosing based on weight
    CVVHSee above dosing based on weight

    ✱On day one, give second dose 8 hours after first dose. Total course is 6 doses.

    ARTEMETHER-LUMEFANTRINE [#grey] | Coartem
  • ATOVAQUONE Mepron
  • Atovaquone PO: Pneumocystis jirovecii pneumonia prophylaxis

    All CrCl.1500mgQ24H
    Hemodialysis
    Peritoneal dialysisNO DATA
    CVVH1500mgQ24H
    ATOVAQUONE [#grey] | Mepron
  • Atovaquone PO: Pneumocystis jirovecii pneumonia treatment or prophylaxis, babesiosis treatment

    All CrCl.750mgQ12H
    Hemodialysis
    Peritoneal dialysisNO DATA
    CVVH750mgQ12H
    ATOVAQUONE [#grey] | Mepron
  • Atovaquone PO: toxoplasmosis treatment

    All CrCl.1500mgQ12H
    Hemodialysis
    Peritoneal dialysisNO DATA
    CVVH1500mgQ12H
    ATOVAQUONE [#grey] | Mepron
  • ATOVAQUONE-PROGUANIL Malarone
  • Atovaquone-proguanil PO: P. falciparum malaria treatment

    All CrCl1000mg/400mgQ24H x3 days
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA
    ATOVAQUONE-PROGUANIL [#grey] | Malarone
  • Atovaquone-proguanil PO: P. falciparum malaria prophylaxis

    CrCl ≥30250mg/100mgQ24H
    CrCl <30AVOID
    HemodialysisAVOID
    Peritoneal dialysisAVOID
    CVVHAVOID
    ATOVAQUONE-PROGUANIL [#grey] | Malarone
  • AZITHROMYCIN Azasite, Zithromax TRI-PAK, Zithromax Z-Pak, Zmax
  • Azithromycin PO/IV: bacterial sinusitis, community acquired pneumonia, skin and soft tissue infections, pertussis

    All CrCl250–500mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    On dialysis days give post-HD

    AZITHROMYCIN [#grey] | Azasite, Zithromax TRI-PAK, Zithromax Z-Pak, Zmax
  • Azithromycin PO: MAC prophylaxis

    All CrCl1200mgQWEEK
    Hemodialysis
    Peritoneal dialysis
    CVVH
    AZITHROMYCIN [#grey] | Azasite, Zithromax TRI-PAK, Zithromax Z-Pak, Zmax
  • AZTREONAM Azactam
  • Aztreonam IV ✱ID✱

    CrCl >502gmQ8H
    10–501gmQ8H
    <50500mgQ8H
    Hemodialysis1–2gm x1, then 500mgQ8H
    Peritoneal dialysis500mgQ8H
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    AZTREONAM [#grey] | Azactam
  • BALOXAVIR Xofluza
  • Baloxavir PO ✱ID✱

    CrCl ≥50, weight ≥80kg80mgx1
    ≥50, weight <80kg40mgx1
    <50NO DATA
    HemodialysisNO DATA
    Peritoneal dialysis.NO DATA
    CVVHNO DATA
    BALOXAVIR [#grey] | Xofluza
  • BEDAQUILINE Sirturo
  • Bedaquiline PO

    All CrCl400mg Q24H x2 weeks, then 200mgThree times weekly
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    Only able to be obtained through Metro Medical Speciality Pharmacy after consultation with MTB expert

    BEDAQUILINE [#grey] | Sirturo
  • BEZLOTOXUMAB Zinplava
  • Bezlotoxumab IV: CDI recurrence ✱ID✱

    All CrCl10mg/kgx1
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Not generally used for inpatients, please follow local guidelines

    BEZLOTOXUMAB [#grey] | Zinplava
  • CEFACLOR Ceclor Pulvules, Ceclor CD, Raniclor
  • Cefaclor PO

    All CrCl250–500mgQ8H
    Hemodialysis
    Peritoneal dialysis
    CVVHNO DATA
    CEFACLOR [#grey] | Ceclor Pulvules, Ceclor CD, Raniclor
  • CEFADROXIL Duricef
  • Cefadroxil PO

    CrCl >50500–1000mgQ12H
    25–50500mgQ12H
    10–25500mgQ24H
    <10500mgQ36H
    Hemodialysis500–1000mgPost-HD
    Peritoneal dialysis500mgQ24H
    CVVHNO DATA
    CEFADROXIL [#grey] | Duricef
  • CEFAZOLIN Ancef, Kefzol
  • Cefazolin IV

    CrCl >502gmQ8H
    10–502gmQ12H
    <102gmQ24H
    Hemodialysis1gm Q24H OR 2–3gm Post-HD
    Peritoneal dialysis1gmQ24H
    CVVHSee CVVH Dosing

    For Post-HD dosing, consider using 2gm and 3gm with the 48- and 72-hr interdialytic periods, respectively; On dialysis days give post-HD

    CEFAZOLIN [#grey] | Ancef, Kefzol
  • CEFDINIR Omnicef Omni-Pac
  • Cefdinir PO

    CrCl ≥30300mgQ12H
    <30300mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVHNO DATA

    On dialysis days give post-HD

    CEFDINIR [#grey] | Omnicef Omni-Pac
  • CEFEPIME Maxipime ADD-Vantage
  • Cefepime IV: febrile neutropenia, pneumonia, cystic fibrosis, non-UTI Pseudomonas aeruginosa

    CrCl ≥602gmQ8H
    30–592gmQ12H
    10–292gmQ24H
    <101gmQ24H
    Hemodialysis1gm Q24H OR 2gm Post-HD
    Peritoneal dialysis1gmQ24H
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    CEFEPIME [#grey] | Maxipime ADD-Vantage
  • Cefepime IV: other infections

    CrCl ≥601gm / 2gmQ8H / Q12H
    30–591gm / 2gmQ12H / Q24H
    10–291gmQ24H
    <10
    Hemodialysis1gm Q24H OR 2gm Post-HD
    Peritoneal dialysis1gm x1, then 0.5gmQ24H
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    CEFEPIME [#grey] | Maxipime ADD-Vantage
  • Cefepime IV: alternative dosing; may replace 2gm Q8H and 2gm Q12H dosing; EXCEPT for febrile neutropenia and CNS infections

    CrCl ≥501gmQ6H
    30–491gmQ8H
    10–291gmQ12H
    <101gmQ24H
    Hemodialysis1gm Q24H OR 2gm Post-HD
    Peritoneal dialysis1gmQ24H
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    CEFEPIME [#grey] | Maxipime ADD-Vantage
  • CEFIDEROCOL Fetroja
  • Cefiderocol IV ✱ID✱

    CrCl ≥1202gmQ6H
    60–1192gmQ8H
    30–591.5gmQ8H
    15–291gmQ8H
    <150.75gmQ12H
    Hemodialysis
    Peritoneal dialysisNO DATA
    CVVHSee CVVH Dosing
    CEFIDEROCOL [#grey] | Fetroja
  • CEFIXIME Suprax
  • Cefixime PO

    CrCl ≥60400mgQ24H
    21–59300mgQ24H
    ≤20200mgQ24H
    Hemodialysis300mgQ24H
    Peritoneal dialysis200mgQ24H
    CVVHNO DATA
    CEFIXIME [#grey] | Suprax
  • Cefixime PO: uncomplicated gonorrhea

    All CrCl400mgx1
    Hemodialysis
    Peritoneal dialysis
    CVVHNO DATA
    CEFIXIME [#grey] | Suprax
  • CEFOTAXIME Claforan ADD-Vantage
  • Cefotaxime IV

    CrCl >502gmQ6H
    10–502gmQ8H
    <102gmQ24H
    Hemodialysis0.5–2gmQ24H
    Peritoneal dialysis1gmQ24H
    CVVHSee CVVH Dosing

    2gm Q4H in severe infections; On dialysis days give post-HD

    CEFOTAXIME [#grey] | Claforan ADD-Vantage
  • CEFOTETAN Cefotan
  • Cefotetan IV

    CrCl >301–2gmQ12H
    <301–2gmQ24H
    Hemodialysis1gmPost-HD
    Peritoneal dialysis1gmQ24H
    CVVH1–2gmQ24h

    On dialysis days give post-HD

    CEFOTETAN [#grey] | Cefotan
  • CEFOXITIN Mefoxin
  • Cefoxitin IV

    CrCl >501–2gmQ6–Q8H
    10–501–2gmQ8–12H
    <101–2gmQ24–48H
    Hemodialysis1gmPost-HD
    Peritoneal dialysis1gmQ24H
    CVVH1–2gmQ8–12H

    On dialysis days give post-HD

    CEFOXITIN [#grey] | Mefoxin
  • Cefoxitin IV: nontuberculous mycobacterial infections

    CrCl >503gm / 2gmQ6H / Q4H
    10–503gm / 2gmQ8H / Q6H
    <103gmQ24H–Q48H
    Hemodialysis3gmPost-HD
    Peritoneal dialysis3gmQ24H
    CVVH3gm / 2gmQ12H / Q8H

    On dialysis days give post-HD

    CEFOXITIN [#grey] | Mefoxin
  • CEFPODOXIME Vantin
  • Cefpodoxime PO

    CrCl ≥30200–400mgQ12H
    <30200–400mgQ24H
    Hemodialysis200–400mgPost-HD
    Peritoneal dialysis200–400mgQ24H
    CVVHNO DATA

    On dialysis days give post-HD

    CEFPODOXIME [#grey] | Vantin
  • CEFPROZIL Cefzil
  • Cefprozil PO: acute bacterial exacerbation of chronic bronchitis, uncomplicated skin and soft tissue infection

    CrCl ≥50500mgQ12H
    <50250mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVHNO DATA

    On dialysis days give post-HD

    CEFPROZIL [#grey] | Cefzil
  • Cefprozil PO: pharyngitis, tonsillitis

    CrCl ≥50500mgQ24H
    <50250mgQ24H
    Hemodialysis250mgPost-HD
    Peritoneal dialysis250mgQ24H
    CVVHNO DATA

    On dialysis days give post-HD

    CEFPROZIL [#grey] | Cefzil
  • CEFTAROLINE FOSAMIL Teflaro
  • Ceftaroline fosamil IV: community acquired pneumonia, skin and soft tissue infections ✱ID✱

    CrCl ≥50600mgQ12H
    30–49400mgQ12H
    10–29300mgQ12H
    <10200mgQ12H
    Hemodialysis
    Peritoneal dialysisNO DATA
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    CEFTAROLINE FOSAMIL [#grey] | Teflaro
  • Ceftaroline fosamil IV: MRSA bacteremia, MRSA pneumonia, severe MRSA infections ✱ID✱

    CrCl ≥50600mgQ8H
    30–49400mgQ8H
    10–29300mgQ8H
    <10200mgQ8H
    Hemodialysis
    Peritoneal dialysisNO DATA
    CVVHSee CVVH Dosing

    On dialysis days give post-HD; Consider Q12H in cases of Gram positive synergy dosing

    CEFTAROLINE FOSAMIL [#grey] | Teflaro
  • CEFTAZIDIME Fortaz, Tazicef, Ceptaz, Tazidime, Tazicef Novaplus
  • Ceftazidime IV: febrile neutropenia, pneumonia, bacteremia, sepsis

    CrCl >502gmQ8H
    31–502gmQ12H
    16–302gmQ24H
    5–152gm x1, then 1gmQ24H
    <52gm x1, then 1gmQ48H
    Hemodialysis2gm x1, then 1gm Q24H OR 2gm Post-HD
    Peritoneal dialysis2gm x1, then 1gmQ24H
    CVVHSee CVVH Dosing

    Max dose 8gm/day; Meningitis max dose up to 2gm Q6H; On dialysis days give post-HD

    CEFTAZIDIME [#grey] | Fortaz, Tazicef, Ceptaz, Tazidime, Tazicef Novaplus
  • Ceftazidime IV: UTI, if urosepsis follow above dosing recommendations

    CrCl >501gmQ8H
    31–501gmQ12H
    5–301gmQ24H
    <51gmQ48H
    Hemodialysis1gm x1, then 0.5gmQ24H
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    CEFTAZIDIME [#grey] | Fortaz, Tazicef, Ceptaz, Tazidime, Tazicef Novaplus
  • CEFTAZIDIME-AVIBACTAM Avycaz ceftaz-avi
  • Ceftazidime-avibactam IV ✱ID✱

    CrCl >502.5gmQ8H
    31–501.25–2.5gm x1 then 1.25 gmQ8H
    16–301.25gmQ12H
    5–151.25gmQ24H
    <51.25gmQ48H
    Hemodialysis (CrCl 6–15 mL/min)1.25gmQ24H
    Hemodialysis (CrCl ≤5 mL/min)1.25gmQ48H
    Peritoneal dialysisNO DATA
    CVVHSee CVVH Dosing

    On dialysis days give post-HD; Each 2.5gm vial contains 2gm of ceftazidime and 0.5gm of avibactam

    CEFTAZIDIME-AVIBACTAM [#grey] | Avycaz ceftaz-avi
  • CEFTOLOZANE-TAZOBACTAM Zerbaxa ceftolo-tazo
  • Ceftolozane-tazobactam IV: complicated urinary tract infections and complicated intra-abdominal infections ✱ID✱

    CrCl >501500mgQ8H
    30–50750mgQ8H
    15–29375mgQ8H
    <15NO DATA
    Hemodialysis750mg x1 then 150mgQ8H
    Peritoneal dialysisNO DATA
    CVVHSee CVVH Dosing

    On dialysis days give post-HD; Each 1500mg vial contains 1000mg of ceftolozane and 500mg of tazobactam

    CEFTOLOZANE-TAZOBACTAM [#grey] | Zerbaxa ceftolo-tazo
  • Ceftolozane-tazobactam IV: ventilator-associated pneumonia or MDRO pathogens ✱ID✱

    CrCl >503000mgQ8H
    30–501500mgQ8H
    15–29750mgQ8H
    <15NO DATA
    Hemodialysis2250mg x1 then 450mgQ8H
    Peritoneal dialysisNO DATA
    CVVHSee CVVH Dosing

    On dialysis days give post-HD; Each 1500mg vial contains 1000mg of ceftolozane and 500mg of tazobactam

    CEFTOLOZANE-TAZOBACTAM [#grey] | Zerbaxa ceftolo-tazo
  • CEFTRIAXONE Rocephin ADD-Vantage
  • Ceftriaxone IV: bloodstream infections, bone or joint infections, pneumonia, intra-abdominal infections, Lyme disease

    All CrCl2gmQ24H
    Hemodialysis
    Peritoneal dialysis1gmQ12–24H
    CVVH2gmQ24H

    On dialysis days give post-HD

    CEFTRIAXONE [#grey] | Rocephin ADD-Vantage
  • Ceftriaxone IV: urinary tract infections, skin and soft tissue infections, pneumonia, intra-abdominal infections, SBP prophylaxis

    All CrCl1gmQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH2gmQ24H

    On dialysis days give post-HD

    CEFTRIAXONE [#grey] | Rocephin ADD-Vantage
  • Ceftriaxone IV: bacterial meningitis or Enterococcal endocarditis

    All CrCl2gmQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    On dialysis days give post-HD

    CEFTRIAXONE [#grey] | Rocephin ADD-Vantage
  • Ceftriaxone IM: gonorrhea

    All CrCl500mgx1
    Hemodialysis
    Peritoneal dialysis
    CVVH

    For patients ≥150kg, ceftriaxone 1000 mg should be administered

    CEFTRIAXONE [#grey] | Rocephin ADD-Vantage
  • CEFUROXIME Ceftin, Kefurox, Zinacef, Zinacef ADD-Vantage, Zinacef TwistVial
  • Cefuroxime IV

    CrCl >20750–1500mgQ8H
    10–20750–1500mgQ12H
    <10750–1500mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    CEFUROXIME [#grey] | Ceftin, Kefurox, Zinacef, Zinacef ADD-Vantage, Zinacef TwistVial
  • Cefuroxime PO

    CrCl ≥10250–500mgQ12H
    <10250–500mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    CEFUROXIME [#grey] | Ceftin, Kefurox, Zinacef, Zinacef ADD-Vantage, Zinacef TwistVial
  • CEPHALEXIN Keflex, Biocef, Zartan, Panixine, Daxbia
  • Cephalexin PO

    CrCl >50500–1000mgQ6H
    10–50500–1000mgQ8H
    <50250–500mgQ12–24H
    Hemodialysis
    Peritoneal dialysis
    CVVHNO DATA

    On dialysis days give post-HD. Consider higher doses in obesity; Max dose 4 gm/day.

    CEPHALEXIN [#grey] | Keflex, Biocef, Zartan, Panixine, Daxbia
  • CHLORAMPHENICOL
  • Chloramphenicol IV

    All CrCl12.5–25mg/kgQ6H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    CHLORAMPHENICOL [#grey] |
  • CHLOROQUINE PHOSPHATE Aralen Phosphate, Aralen Hydrochloride
  • Chloroquine Phosphate PO: malaria treatment

    All CrCl | 1gm x1, then 500mg at 6, 24, and 48h after initial doseHemodialysis | 1gm x1, then 500mg at 6, 24, and 48h after initial dosePeritoneal dialysis | 1gm x1, then 500mg at 6, 24, and 48h after initial doseCVVH | 1gm x1, then 500mg at 6, 24, and 48h after initial dose

    500mg of chloroquine phosphate salt is equivalent to 300mg of chloroquine base

    CHLOROQUINE PHOSPHATE [#grey] | Aralen Phosphate, Aralen Hydrochloride
  • Chloroquine Phosphate PO: malaria prophylaxis

    All CrCl500mgonce weekly
    Hemodialysis
    Peritoneal dialysis
    CVVH

    500mg of chloroquine phosphate salt is equivalent to 300mg of chloroquine base; Start 1-2 weeks before arrival to endemic area, continue weekly during travel and for 4 weeks after leaving endemic area

    CHLOROQUINE PHOSPHATE [#grey] | Aralen Phosphate, Aralen Hydrochloride
  • CIDOFOVIR Vistide
  • Cidofovir IV ✱ID✱

    CrCl ≥555mg/kgQweek x2 doses, then Q2weeks
    <55Consult ID
    HemodialysisAVOID
    Peritoneal dialysisAVOID
    CVVHSee CVVH Dosing

    Consider dose adjustments in discussion with ID in patients with severe renal dysfunction; Pre and post hydration with sodium chloride 0.9%; Probenecid 2gm 3 hours prior to and 1gm 2hr and 8h post infusion

    CIDOFOVIR [#grey] | Vistide
  • Cidofovir IV: BK virus nephropathy ✱ID✱

    CrCl ≥100.25–1mg/kgx1
    CrCl <10NO DATA

    Repeat doses will be determined by the renal transplant team in conjunction with ID. Probenecid should not be co-administered with cidofovir when it is being used to treat BK nephropathy

    CIDOFOVIR [#grey] | Vistide
  • CIPROFLOXACIN Cipro, Proquin XR
  • Ciprofloxacin IV

    CrCl ≥30400mgQ8–12H
    <30400mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    On dialysis days give post-HD; If critically ill or treating pneumonia, q8h can be used

    CIPROFLOXACIN [#grey] | Cipro, Proquin XR
  • Ciprofloxacin PO

    CrCl ≥30500–750mgQ12H
    <30500mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH500–750mgQ24H

    Consider higher dose for PsA, MDR, critically ill, or PNA. Consider 250-500 mg for empiric UTI coverage. On dialysis days give post-HD.

    CIPROFLOXACIN [#grey] | Cipro, Proquin XR
  • Ciprofloxacin PO: Spontaneous Bacterial Peritonitis Prophylaxis

    All CrCl500mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    On dialysis days give post-HD

    CIPROFLOXACIN [#grey] | Cipro, Proquin XR
  • CLARITHROMYCIN Biaxin XL
  • Clarithromycin PO

    CrCl ≥30500mgQ12H
    <30250mgQ12H
    Hemodialysis500mgQ24H
    Peritoneal dialysisNO DATA
    CVVH250–500mgQ12H

    On dialysis days give post-HD

    CLARITHROMYCIN [#grey] | Biaxin XL
  • CLINDAMYCIN Biaxin XL
  • Clindamycin PO: mild-to-moderate infections

    All CrCl150–450mgQ6–8H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    CLINDAMYCIN [#grey] | Biaxin XL
  • Clindamycin PO: complicated skin and soft tissue infections, pneumonia, or bone & joint infections due to MRSA

    All CrCl600mgQ8H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    CLINDAMYCIN [#grey] | Biaxin XL
  • Clindamycin Phosphate IV

    All CrCl600–900mgQ8H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Serious life threatening infections up to 2,700mg daily

    CLINDAMYCIN [#grey] | Biaxin XL
  • CLOFAZIMINE Biaxin XL
  • Clofazimine PO: nontuberculous mycobacterial infections

    All CrCl100mgQ24H
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    Available for compassionate use for MDR MAC; Requires emergency IRB for dispensing, ID consult recommended

    CLOFAZIMINE [#grey] | Biaxin XL
  • COLISTIN Coly Mycin M
  • Colistimethate IV ✱ID✱

    CrCl ≥70300mg x1, then 150mgQ12H
    60–69300mg x1, then 140mgQ12H
    50–59300mg x1, then 125mgQ12H
    40–49300mg x1, then 110mgQ12H
    30–39300mg x1, then 100mgQ12H
    20–29300mg x1, then 90mgQ12H
    10–19300mg x1, then 80mgQ12H
    <10
    Hemodialysis300mg x1, then 130–170mg✱Q24H
    Peritoneal dialysisNO DATA
    CVVHSee CVVH Dosing

    Dose in terms of colistin base activity (CBA). 1 vial = 150mg CBA = 360mg colistimethate sodium (CMS) = 4.5million units CMS; Dose based on ideal body weight in obesity; ✱Give 130mg on non-HD days and 170mg on HD days; on dialysis days give post-HD; See MGH Dosing Guidelines

    COLISTIN [#grey] | Coly Mycin M
  • CYCLOSERINE PO Seromycin
  • Cycloserine PO: tuberculosis ✱ID✱

    CrCl ≥10250mgQ24H
    <10250–500mgQ36–48H
    Hemodialysis250mgQ24H
    Peritoneal dialysisNO DATA
    CVVH250–500mgQ24H

    TDM goal peak is <35 mcg/mL, dose may be escalated over 2-week period to a max dose of 1000mg/day; dosing should always be discussed with MTB expert; Consider supplemental pyridoxine

    CYCLOSERINE PO [#grey] | Seromycin
  • DALBAVANCIN Dalvance
  • Dalbavancin IV: MRSA skin and soft tissue infection ✱ID✱

    CrCl ≥301500mgx1
    <301125mgx1
    Hemodialysis1500mgx1
    Peritoneal dialysisNO DATA
    CVVH1125mgx1

    Dalbavancin is not removed by hemodialysis

    DALBAVANCIN [#grey] | Dalvance
  • Dalbavancin IV: osteomyelitis ✱ID✱

    CrCl ≥301500mgqweek x2
    <30NO DATA
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    Based on Rappo et al. OFID. 2018;6(1):ofy331; Dalbavancin is not removed by hemodialysis

    DALBAVANCIN [#grey] | Dalvance
  • DAPSONE PJP PCP
  • Dapsone PO: Pneumocystis jirovecii pneumonia treatment or prophylaxis

    All CrCl100mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Treatment requires addition of trimethoprim 5mg/kg TID. Consider G6PD testing in high risk patients.

    DAPSONE [#grey] | PJP PCP
  • Dapsone PO: Pneumocystis jirovecii pneumonia prophlaxis alternate dosing

    All CrCl50mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Consider G6PD testing in high risk patients.

    DAPSONE [#grey] | PJP PCP
  • DAPTOMYCIN Cubicin RF
  • Daptomycin IV: MRSA bacteremia or endocarditis ✱ID✱

    CrCl ≥308mg/kgQ24H
    <308mg/kgQ48H
    Hemodialysis8mg/kg Q48H OR 8–12mg/kg post-HD
    Peritoneal dialysis8mg/kgQ48H
    CVVHSee CVVH Dosing

    Do not use for pulmonary infections. For Post-HD dosing, consider using 8 and 12mg/kg with the 48- and 72-hr interdialytic period, respectively. Round dose to the nearest 50mg.

    DAPTOMYCIN [#grey] | Cubicin RF
  • Daptomycin IV: VRE bacteremia or endocarditis ✱ID✱

    CrCl ≥308–12mg/kgQ24H
    <308–12mg/kgQ48H
    Hemodialysis8–12mg/kg Q48H OR 8–12mg/kg post-HD
    Peritoneal dialysis8–12mg/kgQ48H
    CVVHSee CVVH Dosing

    Do not use for pulmonary infections. For Post-HD dosing, consider using 8 and 12mg/kg with the 48- and 72-hr interdialytic period, respectively. Round dose to the nearest 50mg.

    DAPTOMYCIN [#grey] | Cubicin RF
  • Daptomycin IV: Skin and soft tissue infections ✱ID✱

    CrCl ≥304mg/kgQ24H
    <304mg/kgQ48H
    Hemodialysis4mg/kg Q48H OR 4–6mg/kg post-HD
    Peritoneal dialysis4mg/kgQ48H
    CVVHSee CVVH Dosing

    Do not use for pulmonary infections. For Post-HD dosing, consider using 4 and 6mg/kg with the 48- and 72-hr interdialytic period, respectively. Round dose to the nearest 50mg.

    DAPTOMYCIN [#grey] | Cubicin RF
  • DELAFLOXACIN Baxdela
  • Delafloxacin PO: pneumonia, skin and soft tissue infections ✱ID✱

    eGFR ≥15450mgQ12H
    <15Not recommended
    HemodialysisNot recommended

    MDRD eGFR (mL/min/1.73m2) = 175 x (serum creatinine) - 1.154 x (age) - 0.203 x (0.742 if female) x (1.212 if African American); MDCalc calculator

    DELAFLOXACIN [#grey] | Baxdela
  • Delafloxacin IV: pneumonia, skin and soft tissue infections ✱ID✱

    eGFR ≥30300mgQ12H
    15–29200mgQ12H
    <15Not recommended
    HemodialysisNot recommended

    MDRD eGFR (mL/min/1.73m2) = 175 x (serum creatinine) - 1.154 x (age) - 0.203 x (0.742 if female) x (1.212 if African American); MDCalc calculator

    DELAFLOXACIN [#grey] | Baxdela
  • DICLOXACILLIN Dycill, Dynapen
  • Dicloxacillin Sodium PO

    All CrCl125–500mgQ6H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Max dose 2gm/day

    DICLOXACILLIN [#grey] | Dycill, Dynapen
  • DOXYCYCLINE Acticlate, Adoxa CK, Adoxa Pak, Adoxa TT, Alodox, Avidoxy, Doryx, Mondoxyne NL, Monodox, Morgidox, Okebo, Oracea, Oraxyl, Periostat Targadox, Vibramycin calcium, Vibramycin Hyclate, Vibramycin monohydrate, Vibra-Tabs
  • Doxycycline PO/IV

    All CrCl100mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    DOXYCYCLINE [#grey] | Acticlate, Adoxa CK, Adoxa Pak, Adoxa TT, Alodox, Avidoxy, Doryx, Mondoxyne NL, Monodox, Morgidox, Okebo, Oracea, Oraxyl, Periostat Targadox, Vibramycin calcium, Vibramycin Hyclate, Vibramycin monohydrate, Vibra-Tabs
  • ERAVACYCLINE Xerava
  • Eravacycline IV ✱ID✱

    All CrCl1mg/kgQ12H
    Severe hepatic impairment (Child-Pugh C)1mg/kg Q12H x2, then 1mg/kgQ24H
    Concomitant strong CYP3A inducer1.5mg/kgQ12H
    Hemodialysis1mg/kgQ12H
    CVVH
    ERAVACYCLINE [#grey] | Xerava
  • ERTAPENEM Invanz ADD-Vantage
  • Ertapenem IV ✱ID✱

    CrCl ≥301gmQ24H
    <30500mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    ERTAPENEM [#grey] | Invanz ADD-Vantage
  • ERYTHROMYCIN EES, EryPed, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab
  • Erythromycin Lactobionate IV

    CrCl ≥1015–20mg/kgQ6H
    <107.5–10mg/kgQ6H
    Hemodialysis
    Peritoneal dialysis
    CVVH15–20mg/kgQ6H

    Max dose 4gm/day

    ERYTHROMYCIN [#grey] | EES, EryPed, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab
  • Erythromycin Lactobionate IV: GI motility

    All CrCl70–200mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    ERYTHROMYCIN [#grey] | EES, EryPed, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab
  • Erythromycin PO tablets

    All CrCl250–500mgQ6H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Extended release and film coated tablets should be dosed off of the erythromycin base component

    ERYTHROMYCIN [#grey] | EES, EryPed, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab
  • Erythromycin Ethylsuccinate PO solution

    All CrCl400–800mgQ6H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    ERYTHROMYCIN [#grey] | EES, EryPed, Ery-Tab, Erythrocin Lactobionate, Erythrocin Stearate Filmtab
  • ETHAMBUTOL Myambutol
  • Ethambutol PO: tuberculosis

    CrCl ≥3015–25mg/kgQ24H
    <3015–25mg/kg3x/week
    Hemodialysis15–25mg/kgQ6H
    Peritoneal dialysis
    CVVHNO DATA

    Max Dose 2.5gm/day; On dialysis days give post-HD (supplemental doses for additional sessions not required)

    ETHAMBUTOL [#grey] | Myambutol
  • ETHIONAMIDE Trecator, Trecator-SC
  • Ethionamide PO: tuberculosis

    All CrCl250mgQ12–24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Dose may be escalated over 2-week period to a max dose of 1000mg/day; dosing should always be discussed with MTB expert; Consider supplemental pyridoxine

    ETHIONAMIDE [#grey] | Trecator, Trecator-SC
  • FAMCICLOVIR Famvir
  • Famciclovir PO: herpes zoster

    CrCl ≥60500mgQ8H
    40–59500mgQ12H
    20–39500mgQ24H
    <20250mgQ24H
    Hemodialysis250mgPost-HD
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    On dialysis days give post-HD

    FAMCICLOVIR [#grey] | Famvir
  • Famciclovir PO: HSV-recurrent genital herpes

    CrCl ≥601000mgQ12H x1d
    40–59500mgQ12H x1d
    20–39500mgx1
    <20250mgx1
    Hemodialysis
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    On dialysis days give post-HD

    FAMCICLOVIR [#grey] | Famvir
  • Famciclovir PO: Suppression for HSV-recurrent orolabial and genital HSV infection in HIV-infected patients

    CrCl >60250mgQ12H
    20–40125mgQ12H
    <20125mgQ24H
    Hemodialysis125mgPost-HD
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    On dialysis days give post-HD

    FAMCICLOVIR [#grey] | Famvir
  • Famciclovir PO: MGH-only – HSV/VZV prophylaxis in low CMV risk kidney, liver, and heart transplants

    CrCl ≥30500mgQ24H
    <30250mgQ24H

    On dialysis days give post-HD

    FAMCICLOVIR [#grey] | Famvir
  • FIDAXOMICIN Dificid
  • Fidaxomicin PO: Clostridioides difficile infection ✱ID✱

    All CrCl200mgQ12H x10d
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Please refer to the MGB C. difficile management guidelines for criteria for use

    FIDAXOMICIN [#grey] | Dificid
  • Fidaxomicin PO: Pulse dosing for recurrent Clostridioides difficile infection ✱ID✱

    All CrCl200mgQ12H x5d, then every other day x20d
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Please refer to the MGB C. difficile management guidelines for criteria for use

    FIDAXOMICIN [#grey] | Dificid
  • FLUCONAZOLE Diflucan
  • Fluconazole PO/IV: invasive candidiasis treatment

    CrCl ≥50800mg x1, 400mgQ24H
    <50400mg x1, 200mgQ24H
    Hemodialysis400–800mg x1, 200mg Q24H OR 400–800mg x1, 400mg post-HD
    Peritoneal dialysis400mg x1, 200mgQ24H
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    FLUCONAZOLE [#grey] | Diflucan
  • Fluconazole PO/IV: invasive candidiasis treatment, alternative weight-based treatment for extremes in body weight

    CrCl ≥5012mg/kg x1, 6mg/kgQ24H
    <506mg/kg x1, 3mg/kgQ24H
    Hemodialysis6mg/kg x1, 3mg/kg Q24H OR 6mg/kg x1, 6mg/kg post-HD
    Peritoneal dialysis6mg/kg x1, 3mg/kgQ24H
    CVVHSee CVVH Dosing

    On dialysis days give post-HD; round doses to nearest 50mg

    FLUCONAZOLE [#grey] | Diflucan
  • Fluconazole PO: vagin*l candidiasis

    CrCl ≥50150mgQ72H x1–3 doses
    <50
    Hemodialysis
    Peritoneal dialysis
    CVVH

    On dialysis days give post-HD

    FLUCONAZOLE [#grey] | Diflucan
  • Fluconazole PO/IV: thrush/oropharyngeal candidiasis

    CrCl ≥50200mgQ24H
    <50200mg x1, then 100mgQ24H
    Hemodialysis200mg x1, then 200mgPost-HD
    Peritoneal dialysis200mg x1, then 100mgQ24H
    CVVH400mgQ24H

    On dialysis days give post-HD

    FLUCONAZOLE [#grey] | Diflucan
  • Fluconazole PO/IV: prophylaxis dosing

    CrCl ≥50200–400mgQ24H
    <50100–200mgQ24H
    Hemodialysis400mgPost-HD
    Peritoneal dialysis100–200mgQ24H
    CVVH200–400mgQ24H

    On dialysis days give post-HD

    FLUCONAZOLE [#grey] | Diflucan
  • FLUCYTOSINE Ancobon
  • Flucytosine PO: cryptococcal meningitis

    CrCl ≥4025mg/kgQ6H
    20–3925mg/kgQ12H
    10–1925mg/kgQ24H
    <1025mg/kgQ24–48H
    Hemodialysis25mg/kgQ24H✱ OR post-HD
    Peritoneal dialysis25mg/kgQ48–72H
    CVVHSee CVVH Dosing

    ✱For severe infections. Consider TDM to guide dosing (goal 2-hour post dose level 30-80 mcg/mL). On dialysis days give post-HD; Use in combination with systemic Liposomal Amphotericin B

    FLUCYTOSINE [#grey] | Ancobon
  • FOSCARNET Foscavir
  • Foscarnet IV: CMV induction, HHV-6 ✱ID✱

    CrCl >1.4mL/min/kg✱60mg/kgQ8H
    1.0–1.4mL/min/kg✱45mg/kgQ8H
    0.8–1.0mL/min/kg✱50mg/kgQ12H
    0.6–0.8mL/min/kg✱40mg/kgQ12H
    0.5–0.6mL/min/kg✱60mg/kgQ24H
    0.4–0.5mL/min/kg✱50mg/kgQ24H
    <0.4mL/min/kg✱Avoid or Consult ID
    Hemodialysis45–60mg/kgPost-HD
    Peritoneal dialysisNO DATA
    CVVHSee CVVH Dosing

    On dialysis days give post-HD; ✱To calculate modified creatinine clearance MDCalc: MALES, mL/min/kg = (140 - age)/(serum creatinine x 72); FEMALES, Use above formula and multiply by 0.85

    FOSCARNET [#grey] | Foscavir
  • Foscarnet IV: CMV maintenance ✱ID✱

    CrCl >1.4mL/min/kg✱120mg/kg/dayQ12–24H
    1.0–1.4mL/min/kg✱90mg/kg/dayQ12–24H
    0.8–1.0mL/min/kg✱65mg/kg/dayQ12–24H
    0.6–0.8mL/min/kg✱105mg/kg/dayQ48H
    0.5–0.6mL/min/kg✱80mg/kg/dayQ48H
    0.4–0.5mL/min/kg✱65mg/kg/dayQ48H
    <0.4mL/min/kg✱Avoid or Consult ID
    Hemodialysis45–60mg/kgPost-HD
    Peritoneal dialysisNO DATA
    CVVH60mg/kgQ48H

    On dialysis days give post-HD; ✱To calculate modified creatinine clearance MDCalc: MALES, mL/min/kg = (140 - age)/(serum creatinine x 72); FEMALES, Use above formula and multiply by 0.85

    FOSCARNET [#grey] | Foscavir
  • Foscarnet IV: HSV-1 or -2 infection ✱ID✱

    CrCl >1.4mL/min/kg✱40mg/kgQ8H
    1.0–1.4mL/min/kg✱30mg/kgQ8H
    0.8–1.0mL/min/kg✱35mg/kgQ12H
    0.6–0.8mL/min/kg✱25mg/kgQ12H
    0.5–0.6mL/min/kg✱40mg/kgQ24H
    0.4–0.5mL/min/kg✱35mg/kgQ24H
    <0.4mL/min/kg✱Avoid or Consult ID
    Hemodialysis45–60mg/kgPost-HD
    Peritoneal dialysisNO DATA
    CVVH40mg/kgQ24H

    On dialysis days give post-HD; ✱To calculate modified creatinine clearance MDCalc: MALES, mL/min/kg = (140 - age)/(serum creatinine x 72); FEMALES, Use above formula and multiply by 0.85

    FOSCARNET [#grey] | Foscavir
  • FOSFOMYCIN Dificid
  • Fosfomycin PO: uncomplicated UTI

    All CrCl3gmx1
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Dissolve 3gm dose in 3-4 oz of water

    FOSFOMYCIN [#grey] | Dificid
  • Fosfomycin PO: complicated UTI, prostatitis

    All CrCl3gmQ 2–3 days
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Dissolve 3gm dose in 3-4 oz of water

    FOSFOMYCIN [#grey] | Dificid
  • GANCICLOVIR Cytovene
  • Ganciclovir IV: CMV, induction ✱ID✱

    CrCl ≥705mg/kgQ12H
    50–695mg/kg x1, 2.5mg/kgQ12H
    25–495mg/kg x1, 2.5mg/kgQ24H
    10–245mg/kg x1, 1.25mg/kgQ24H
    <105mg/kg x1, 1.25mg/kg3x/week
    Hemodialysis5mg/kg x1, 1.25mg/kgPost-HD
    Peritoneal dialysis5mg/kg x1, 1.25mg/kg3x/week
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    GANCICLOVIR [#grey] | Cytovene
  • Ganciclovir IV: CMV, maintenance or prophylaxis ✱ID✱

    CrCl ≥705mg/kgQ24H
    50–695mg/kg x1, 2.5mg/kgQ24H
    25–495mg/kg x1, 1.25mg/kgQ24H
    10–245mg/kg x1, 0.625mg/kgQ24H
    <105mg/kg x1, 0.625mg/kg3x/week
    Hemodialysis5mg/kg x1, 0.625mg/kgPost-HD
    Peritoneal dialysis5mg/kg x1, 0.625mg/kg3x/week
    CVVHSee CVVH Dosing

    No load necessary for valganciclovir to IV transition; On dialysis days give post-HD

    GANCICLOVIR [#grey] | Cytovene
  • GENTAMICIN Garamycin, Cidomycin
  • Gentamicin IV

    Please refer to Site-Specific Aminoglycoside Dosing Guidelines, whenavailable.

    Please contact pharmacy department for help with monitoring serum concentrations and dosage adjustments.

    GENTAMICIN [#grey] | Garamycin, Cidomycin
  • GRISEOFULVIN Grifulvin V, Fulvicin P/G, Fulvicin U/F, Gris-PEG, Grisactin Ultra, Grisactin 250, Grisactin 500, Griseofulicin, Griseofulvic
  • Griseofulvin Microsize: tinea barbae, tinea capitis, tinea corporis, tinea cruris

    All CrCl500mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Take after meal with high fat content

    GRISEOFULVIN [#grey] | Grifulvin V, Fulvicin P/G, Fulvicin U/F, Gris-PEG, Grisactin Ultra, Grisactin 250, Grisactin 500, Griseofulicin, Griseofulvic
  • Griseofulvin Microsize: tinea pedis, tinea unguium

    All CrCl1000mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Take after meal with high fat content

    GRISEOFULVIN [#grey] | Grifulvin V, Fulvicin P/G, Fulvicin U/F, Gris-PEG, Grisactin Ultra, Grisactin 250, Grisactin 500, Griseofulicin, Griseofulvic
  • Griseofulvin Ultramicrosize: tinea barbae, tinea capitis, tinea corporis, tinea cruris

    All CrCl375mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Take after meal with high fat content

    GRISEOFULVIN [#grey] | Grifulvin V, Fulvicin P/G, Fulvicin U/F, Gris-PEG, Grisactin Ultra, Grisactin 250, Grisactin 500, Griseofulicin, Griseofulvic
  • Griseofulvin Ultramicrosize: tinea pedis, tinea unguium

    All CrCl750mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Take after meal with high fat content

    GRISEOFULVIN [#grey] | Grifulvin V, Fulvicin P/G, Fulvicin U/F, Gris-PEG, Grisactin Ultra, Grisactin 250, Grisactin 500, Griseofulicin, Griseofulvic
  • HYDROXYCHLOROQUINE Plaquenil, Quineprox
  • Hydroxychloroquine PO: malaria treatment

    All CrCl | 800mg x1, then 400mg at 6, 24, and 48h after initial doseHemodialysis | 800mg x1, then 400mg at 6, 24, and 48h after initial dosePeritoneal dialysis | 800mg x1, then 400mg at 6, 24, and 48h after initial doseCVVH | 800mg x1, then 400mg at 6, 24, and 48h after initial dose

    Total dose: 2 grams

    HYDROXYCHLOROQUINE [#grey] | Plaquenil, Quineprox
  • Hydroxychloroquine PO: malaria prophylaxis

    All CrCl400mgweekly
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Start 1-2 weeks before arrival to endemic area, continue weekly during travel and for 4 weeks after leaving endemic area

    HYDROXYCHLOROQUINE [#grey] | Plaquenil, Quineprox
  • IMIPENEM-CILASTATIN Primaxin ADD-Vantage
  • Imipenem-cilastatin IV: most bacterial infections ✱ID✱

    CrCl ≥60500mgQ6H
    30–59500mgQ8H
    15–29500mgQ12H
    <15AVOID
    Hemodialysis500mgQ12H
    Peritoneal dialysis250mgQ12H
    CVVHSee CVVH Dosing

    Each 500mg vial contains 500mg of imipenem and 500mg of cilastatin; On dialysis days give post-HD

    IMIPENEM-CILASTATIN [#grey] | Primaxin ADD-Vantage
  • Imipenem-cilastatin IV: most mycobacterial infections ✱ID✱

    CrCl ≥301000mgQ12H
    15–29500mgQ12H
    <15AVOID
    Hemodialysis500mgQ12H
    Peritoneal dialysis250mgQ12H
    CVVHSee CVVH Dosing

    Each 500mg vial contains 500mg of imipenem and 500mg of cilastatin; On dialysis days give post-HD

    IMIPENEM-CILASTATIN [#grey] | Primaxin ADD-Vantage
  • Imipenem-cilastatin IV: Bacterial or mycobacterial infections with intermediate susceptibility to imipenem ✱ID✱

    CrCl ≥90750–1000mgQ6H
    60–89750mgQ8H
    30–59500mgQ6H
    15–29500mgQ12H
    <15AVOID
    Hemodialysis500mgQ12H
    Peritoneal dialysis250mgQ12H
    CVVHSee CVVH Dosing

    Each 500mg vial contains 500mg of imipenem and 500mg of cilastatin; On dialysis days give post-HD

    IMIPENEM-CILASTATIN [#grey] | Primaxin ADD-Vantage
  • IMIPENEM-CILASTATIN AND RELEBACTAM Recarbrio
  • Imipenem-cilastatin and relebactam IV: most bacterial infections ✱ID✱

    CrCl ≥901.25gmQ6H
    60–891gmQ6H
    30–590.75gmQ6H
    15–290.5gmQ6H
    <15AVOID
    Hemodialysis0.5gmQ6H
    Peritoneal dialysisNO DATA
    CVVHSee CVVH Dosing

    Each 1.25gm vial contains 500mg of imipenem, 500mg of cilastatin, and 250mg of relebactam

    IMIPENEM-CILASTATIN AND RELEBACTAM [#grey] | Recarbrio
  • ISAVUCONAZOLE Cresemba
  • Isavuconazonium sulfate PO/IV: invasive aspergillosis, mucormycosis ✱ID✱

    All CrCl372mg Q8H x6 doses, then 372mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    372 mg isavuconazonium sulfate (prodrug of isavuconazole) = 200 mg of isavuconazole

    ISAVUCONAZOLE [#grey] | Cresemba
  • ISONIAZID Nydrazid
  • Isoniazid PO: tuberculosis

    All CrCl300mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Consider supplemental pyridoxine 50-100mg to prevent neurotoxicity; Dosing may be higher in MDR tuberculosiscases; Administer post-HD on dialysis days

    ISONIAZID [#grey] | Nydrazid
  • ITRACONAZOLE Sporanox, Tolsura, Onmel, PulsePak
  • Itraconazole PO suspension: aspergillosis, cryptococcosis, febrile neutropenia, histoplasmosis

    All CrCl200mg Q8H x9 doses, then 200mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Monitoring of serum concentrations is recommended for all serious systemic infections. Target serum concentration: >1mcg/ml after 14 days of therapy

    ITRACONAZOLE [#grey] | Sporanox, Tolsura, Onmel, PulsePak
  • IVERMECTIN Stromectol
  • Ivermectin PO: Strongyloidiasis, cutaneous larva migrans

    All CrCl200mcg/kg/doseQ24H x1
    Hemodialysis
    Peritoneal dialysis
    CVVH

    If any stool re-examinations following treatment show signs of recrudescence of larvae, re-treatment is indicated; For patients with hyperinfection and dissemination, daily drug administration until symptoms resolve with negative laboratory tests for larvae for at least two weeks is recommended; Up to 400mcg/kg x1 dose for Bancroft's filariasis.

    IVERMECTIN [#grey] | Stromectol
  • LEFAMULIN Xenleta
  • Lefamulin PO ✱ID✱

    All CrCl600mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Not studied in and not recommended for patients with moderate (Child-Pugh Class B) or severe hepatic impairment (Child-Pugh Class C).

    LEFAMULIN [#grey] | Xenleta
  • Lefamulin IV ✱ID✱

    All CrCl150mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    Severe hepatic impairment (Child-Pugh C)150mgQ24H
    LEFAMULIN [#grey] | Xenleta
  • LETERMOVIR Prevymis
  • Letermovir PO/IV: CMV prophylaxis in patients post-allogeneic hematopoietic stem cell transplant ✱ID✱

    CrCl >10480mgQ24H
    ≤10NO DATA
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    In patients with CrCl<50 mL/min, accumulation of the IV vehicle, hydroxypropyl betadex, may occur. Oral dosing is preferred when able. Check for drug interactions for potential dose adjustments prior to initiation

    LETERMOVIR [#grey] | Prevymis
  • LEVOFLOXACIN Levaquin
  • Levofloxacin PO/IV: nosocomial and community acquired pneumonia, complicated skin and soft tissue infections, MDR tuberculosis

    CrCl ≥50750mgQ24H
    20–49750mgQ48H
    <20750mg x1, 500mgQ48H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    On dialysis days give post-HD; Doses up to 1000mg may be given for MDR TB, discuss with MTB expert

    LEVOFLOXACIN [#grey] | Levaquin
  • Levofloxacin PO/IV: sinusitis, uncomplicated skin and soft tissue infections, UTI

    CrCl ≥50500mgQ24H
    20–49500mg x1, 250mgQ24H
    <20500mg x1, 250mgQ48H
    Hemodialysis
    Peritoneal dialysis
    CVVH250mgQ24H

    On dialysis days give post-HD; Doses up to 1000mg may be given for MDR TB, discuss with MTB expert

    LEVOFLOXACIN [#grey] | Levaquin
  • LINEZOLID Zyvox
  • Linezolid PO/IV ✱ID✱

    All CrCl600mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing
    LINEZOLID [#grey] | Zyvox
  • Linezolid PO/IV: mycobacterial infections ✱ID✱

    All CrCl600mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    Consider supplemental pyridoxine

    LINEZOLID [#grey] | Zyvox
  • MARIBAVIR Livtencity
  • Maribavir PO: CMV treatment ✱ID✱

    All CrCl400mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    MARIBAVIR [#grey] | Livtencity
  • MEBENDAZOLE Emverm, Vermox
  • Mebendazole PO: Ascariasis, trichuriasis

    All CrCl100mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Most parasitic Infections use the 100mg BID dose, but some may require higher dosing.

    MEBENDAZOLE [#grey] | Emverm, Vermox
  • MEFLOQUINE Lariam
  • Mefloquine PO: Malaria treatment

    All CrCl | 750mg x1, then 500mg 12h laterHemodialysis | 750mg x1, then 500mg 12h laterPeritoneal dialysis | 750mg x1, then 500mg 12h laterCVVH | 750mg x1, then 500mg 12h later

    Alternate dosing: 1250mg x1 dose

    MEFLOQUINE [#grey] | Lariam
  • Mefloquine PO: Malaria prophylaxis

    All CrCl250mgweekly
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Start ≥2 weeks before arrival to endemic area, continue weekly during travel and for 4 weeks after leaving endemic area

    MEFLOQUINE [#grey] | Lariam
  • MEROPENEM Merrem Novaplus
  • Meropenem IV: febrile neutropenia, pneumonia, bacteremia, sepsis, UTIs, gynecologic infections, intra-abdominal infections, mycobacterial infections ✱ID✱

    CrCl >501000mgQ8H
    26–501000mgQ12H
    10–25500mgQ12H
    <10500mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    MEROPENEM [#grey] | Merrem Novaplus
  • Meropenem IV: bacterial meningitis, cystic fibrosis, infection with confirmed elevated MIC to meropenem ✱ID✱

    CrCl >502000mgQ8H
    26–502000mgQ12H
    10–251000mgQ12H
    <101000mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    MEROPENEM [#grey] | Merrem Novaplus
  • Meropenem IV: alternative dosing; may replace 1gm Q8H dosing; EXCEPT for febrile neutropenia and CNS infections ✱ID✱

    CrCl >50500mgQ6H
    26–50500mgQ8H
    10–25500mgQ12H
    <10500mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    On dialysis days give post-HD

    MEROPENEM [#grey] | Merrem Novaplus
  • MEROPENEM-VABORBACTAM Vabomere
  • Meropenem-vaborbactam IV ✱ID✱

    eGFR ≥504gmQ8H
    30–492gmQ8H
    15–292gmQ12H
    <151gmQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    Each 4gm dose contains 2gm of meropenem and 2gm of vaborbactam; MDRD eGFR (mL/min/1.73m2) = 175 x (serum creatinine) - 1.154 x (age) - 0.203 x (0.742 if female) x (1.212 if African American); MDCalc calculator; On dialysis days give post-HD.

    MEROPENEM-VABORBACTAM [#grey] | Vabomere
  • METRONIDAZOLE Flagyl ER, RTU, Likmez, Metro, Protostat, Metryl
  • Metronidazole PO/IV: most indications

    All CrCl500mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    METRONIDAZOLE [#grey] | Flagyl ER, RTU, Likmez, Metro, Protostat, Metryl
  • Metronidazole PO/IV: C. difficile, CNS anaerobic infections

    All CrCl500mgQ8H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    METRONIDAZOLE [#grey] | Flagyl ER, RTU, Likmez, Metro, Protostat, Metryl
  • MICAFUNGIN Mycamine
  • Micafungin IV: febrile neutropenia, candidemia, invasive candidiasis, Candida peritonitis, or abscesses ✱ID✱

    All CrCl100mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    MICAFUNGIN [#grey] | Mycamine
  • Micafungin IV: esophageal candidiasis, refractory aspergillosis, consider for fungal endocarditis ✱ID✱

    All CrCl150mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    MICAFUNGIN [#grey] | Mycamine
  • MINOCYCLINE Dynacin, Minocin, Minocin PAC, Minolira, Solodyn, Ximino, Vectrin, Myrac
  • Minocycline HCl PO/IV: most indications

    All CrCl200mg x1, then 100mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Check with pharmacy for IV availability; Higher doses may be considered in certain MDR infections per IDSA guidance. Discuss with ID Pharmacy or ID for dosing recommendations

    MINOCYCLINE [#grey] | Dynacin, Minocin, Minocin PAC, Minolira, Solodyn, Ximino, Vectrin, Myrac
  • MOXIFLOXACIN Avelox
  • Moxifloxacin PO/IV ✱ID✱

    All CrCl400mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    MOXIFLOXACIN [#grey] | Avelox
  • NAFCILLIN Unipen, Nallpen
  • Nafcillin IV: MSSA bacteremia, endocarditis, meningitis, and pneumonia

    All CrCl2gQ4H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    NAFCILLIN [#grey] | Unipen, Nallpen
  • NITAZOXANIDE Alinia
  • Nitazoxanide PO: cryptosporidiosis, giardiasis

    All CrCl500mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Can potentially increase to 1000mg q12h in immunocompromised patients

    NITAZOXANIDE [#grey] | Alinia
  • NITROFURANTOIN Macrobid SR, Macrobid IR
  • Nitrofurantoin PO (Macrobid SR): uncomplicated female or male UTI

    CrCl ≥30100mgQ12H
    <30AVOID
    HemodialysisAVOID
    Peritoneal dialysisAVOID
    CVVHAVOID

    Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses

    NITROFURANTOIN [#grey] | Macrobid SR, Macrobid IR
  • Nitrofurantoin PO (Macrobid IR): uncomplicated female or male UTI

    CrCl ≥3050-100mgQ6H
    <30AVOID
    HemodialysisAVOID
    Peritoneal dialysisAVOID
    CVVHAVOID

    Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses

    NITROFURANTOIN [#grey] | Macrobid SR, Macrobid IR
  • NYSTATIN Nyamyc, Nystop, Mycostatin Topical, Pedi-Dri, Pediaderm AF
  • Nystatin PO: intestinal infections

    CrCl >50500,000–1,000,000 UQ8H
    ≤50NO DATA
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA
    NYSTATIN [#grey] | Nyamyc, Nystop, Mycostatin Topical, Pedi-Dri, Pediaderm AF
  • OMADACYCLINE Nuzyra
  • Omadacycline IV ✱ID✱

    All CrCl200mg x1, then 100mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    OMADACYCLINE [#grey] | Nuzyra
  • Omadacycline PO ✱ID✱

    All CrCl200mg IV x1 OR 450mg PO Q24H x2, followed by 300mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    An initial IV loading dose is required for respiratory infections. Oral loading doses are appropriate for SSTI

    OMADACYCLINE [#grey] | Nuzyra
  • ORITAVANCIN Kimyrsa, Orbactiv
  • Oritavancin IV: MRSA skin and soft tissue infection ✱ID✱

    CrCl ≥101200mgx1
    <10NO DATA
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    Oritavancin is not removed by HD. Oritavancin may interfere with coagulation assays.

    ORITAVANCIN [#grey] | Kimyrsa, Orbactiv
  • OSELTAMIVIR Tamiflu
  • Oseltamivir Phosphate PO: influenza treatment

    CrCl >6075mgQ12H x5 days
    30–6030mgQ12H x5 days
    10–3030mgQ24H x5 days
    <10Not Recommended
    Hemodialysis30mg x1, then 30mgPost-HD x5 days
    Peritoneal dialysis30mgx1 dose
    CVVHSee CVVH Dosing

    For HD patients, give loading dose immediately, then dose after each hemodialysis session.

    OSELTAMIVIR [#grey] | Tamiflu
  • Oseltamivir Phosphate PO: influenza treatment (ONLY FOR SITES THAT DO NOT STOCK 30mg CAPSULES)

    CrCl >3075mgQ12H x5 days
    10–3075mgQ24H x5 days
    <10
    Hemodialysis75mg x1, then 75mgPost-HD x5 days
    Peritoneal dialysis75mgx1 dose
    CVVHSee CVVH Dosing

    For HD patients, give loading dose immediately, then dose after each hemodialysis session.

    OSELTAMIVIR [#grey] | Tamiflu
  • Oseltamivir Phosphate PO: influenza prophylaxis

    CrCl >6075mgQ24H
    30–6030mgQ24H
    10–3030mgQ48H
    <10Not Recommended
    Hemodialysis30mg x1, then 30mg after alternate HD sessionsPost-HD x5 days
    Peritoneal dialysis30mgx1 dose
    CVVH75mgQ24H

    For HD patients, give dose after dialysis session

    OSELTAMIVIR [#grey] | Tamiflu
  • Oseltamivir Phosphate PO: influenza prophylaxis (ONLY FOR SITES THAT DO NOT STOCK 30mg CAPSULES)

    CrCl >3075mgQ24H
    10–3075mgQ48H
    <10
    Hemodialysis75mg x2Q5 days
    Peritoneal dialysis75mgx1 dose
    CVVH75mgQ24H

    For HD patients, give dose after dialysis session

    OSELTAMIVIR [#grey] | Tamiflu
  • OXACILLIN Oxacillin Sodium ADD-Vantage, Bactocill
  • Oxacillin Sodium IV: MSSA bacteremia, endocarditis, pneumonia, meningitis

    All CrCl2gmQ4H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    OXACILLIN [#grey] | Oxacillin Sodium ADD-Vantage, Bactocill
  • PAROMOMYCIN Humatin, Paromycin
  • Paromomycin PO: intestinal amebiasis

    All CrCl500mgQ6H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    PAROMOMYCIN [#grey] | Humatin, Paromycin
  • PENICILLIN
  • Penicillin G IV: endocarditis, bacteremia, neurosyphilis, pneumonia, sepsis

    CrCl >504 million unitsQ4H
    10–503 million unitsQ4H
    <103 million unitsQ8–12H
    Hemodialysis2 million unitsQ4–6H
    Peritoneal dialysis2 million unitsQ6H
    CVVHSee CVVH Dosing
    PENICILLIN [#grey]
  • Penicillin G IV 24H continuous infusion: endocarditis, bacteremia, neurosyphilis, pneumonia, sepsis

    CrCl >5018-24 million unitsContinuous infusion Q24H
    10–50
    <10
    HemodialysisAVOID – NO DATA
    Peritoneal dialysisAVOID – NO DATA
    CVVHAVOID – NO DATA
    PENICILLIN [#grey]
  • Penicillin G IV

    CrCl >502–4 million unitsQ4H
    10–502–3 million unitsQ6H
    <101–2 million unitsQ8H
    Hemodialysis1–2 million unitsQ4–6H
    Peritoneal dialysis1–2 million unitsQ6H
    CVVHSee CVVH Dosing
    PENICILLIN [#grey]
  • Penicillin V PO (Pen-VK, Veetids): pneumococcal respiratory tract infection, otitis media, pharyngitis, gingivitis, staphylococcal skin and soft tissue infection

    CrCl ≥10250–500mgQ6–8H
    <10250–500mgQ8H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    On dialysis days give post-HD

    PENICILLIN [#grey]
  • Penicillin V PO (Pen-VK, Veetids): prophylaxis for rheumatic fever, chorea, or meningococcal disease post-eculizumab

    All CrCl250–500mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    On dialysis days give post-HD

    PENICILLIN [#grey]
  • Penicillin G Benzathine IM (Bicillin L-A)

    CrCl ≥501.2–2.4 million unitsVaries
    Hemodialysis
    Peritoneal dialysis
    CVVH

    NOT for neurosyphilis; on dialysis days give post-HD

    PENICILLIN [#grey]
  • Penicillin G Procaine IM (Wycillin, Bicillin C-R): neurosyphilis

    CrCl ≥502.4 million unitsQ24H
    10–4975% of normal doseQ24H
    <1050% of normal doseQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH75% of normal doseQ24H

    Plus probenecid 500 mg PO 4x/day; On dialysis days give post-HD. IV penicillin G is preferred for neurosyphilis

    PENICILLIN [#grey]
  • Penicillin G Procaine IM (Wycillin, Bicillin C-R): other infections

    CrCl ≥50600,000–1 million unitsQ24H
    10–4975% of normal doseQ24H
    <1050% of normal doseQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH75% of normal doseQ24H

    Administer post-HD

    PENICILLIN [#grey]
  • PENTAMIDINE PJP, PCP, Nebupent, Pentam 300
  • Pentamidine IV/IM: Pneumocystis jirovecii pneumonia treatment

    All CrCl4mg/kgQ24H x21 days
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Infuse IV over 60min; monitor for hypoglycemia

    PENTAMIDINE [#grey] | PJP, PCP, Nebupent, Pentam 300
  • Pentamidine IV/IM/inhalation: Pneumocystis jirovecii pneumonia prophylaxis

    All CrCl300mgQ4weeks
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Infuse IV over 60min; monitor for hypoglycemia

    PENTAMIDINE [#grey] | PJP, PCP, Nebupent, Pentam 300
  • PERAMIVIR Rapivab
  • Peramivir IV: influenza, acute, uncomplicated

    CrCl >50600mgx1
    30–49200mgx1
    10–29100mgx1
    <10
    Hemodialysis100mgx1 Post HD
    Peritoneal dialysisNO DATA
    CVVHNO DATA
    PERAMIVIR [#grey] | Rapivab
  • PIPERACILLIN-TAZOBACTAM Zosyn piptazo pip-tazo
  • Piperacillin-tazobactam IV: nosocomial pneumonia, febrile neutropenia, cystic fibrosis exacerbations, endometritis

    CrCl >404.5gmQ6H
    20–403.375gmQ6H
    <202.25gmQ6H
    Hemodialysis2.25gmQ8H
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    For elevated MICs, extended infusion dosing is recommended

    PIPERACILLIN-TAZOBACTAM [#grey] | Zosyn piptazo pip-tazo
  • Piperacillin-tazobactam IV: appendicitis, peritonitis, pelvic inflammatory disease, complicated skin and soft tissue infections

    CrCl >403.375gmQ6H
    20–402.25gmQ6H
    <202.25gmQ8H
    Hemodialysis
    Peritoneal dialysis2.25gmQ12H
    CVVHSee CVVH Dosing
    PIPERACILLIN-TAZOBACTAM [#grey] | Zosyn piptazo pip-tazo
  • Piperacillin-tazobactam IV: site-specific extended infusion dosing

    CrCl ≥203.375–4.5gmQ8H
    <203.375–4.5gmQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVHSee CVVH Dosing

    First dose infused over 30 minutes, followed 6 hours later by extended infusion regimen (each dose infused over 4 hours); 4.5gm doses may be used in select critically ill patients; Doses of 2.25gm are not needed if utilizing extended infusion protocol

    PIPERACILLIN-TAZOBACTAM [#grey] | Zosyn piptazo pip-tazo
  • PLAZOMICIN Zemdri
  • Plazomicin IV ✱ID✱

    Please refer to Site-Specific Aminoglycoside Dosing Guidelines, when available.

    Please contact pharmacy department for help with monitoring serum concentrations and dosage adjustments

    PLAZOMICIN [#grey] | Zemdri
  • POLYMIXIN Nuzyra
  • Polymyxin B Sulfate IV ✱ID✱

    All CrCl2–2.5 mg/kg x1, then 1.25–1.5 mg/kgQ12H
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHSee CVVH Dosing

    1 mg = 10,000 IU polymyxin B; see MGH dosing guidelines (Protected Antimicrobial Policy)

    POLYMIXIN [#grey] | Nuzyra
  • POSACONAZOLE Noxafil
  • Posaconazole PO: prophylaxis or treatment ✱ID✱

    All CrCl300mg Q12H x2, then 300mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Tablets & oral suspension cannot be used interchangeably. Tablets cannot be crushed.

    POSACONAZOLE [#grey] | Noxafil
  • Posaconazole IV: prophylaxis or treatment ✱ID✱

    CrCl ≥50300mg Q12H x2, then 300mgQ24H
    <50IV not recommended, however clinical situations may warrant therapy; consult ID
    HemodialysisIV not recommended, however clinical situations may warrant therapy; consult ID
    Peritoneal dialysisIV not recommended, however clinical situations may warrant therapy; consult ID
    CVVHIV not recommended, however clinical situations may warrant therapy; consult ID

    Accumulation of IV vehicle Betadex Sulfobutyl Ether Sodium (SBECD) can occur in patients with CrCl < 50 mL/min; avoid IV formulation unless benefit outweighs risk.

    POSACONAZOLE [#grey] | Noxafil
  • Posaconazole PO oral suspension: treatment ✱ID✱

    All CrCl200mgQ6H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Tablets & oral suspension cannot be used interchangeably. Must be taken with high fat meal. Dosing for the treatment of refractory oropharyngeal candidiasis may vary.

    POSACONAZOLE [#grey] | Noxafil
  • Posaconazole PO oral suspension: prophylaxis ✱ID✱

    All CrCl200mgQ8H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Tablets & oral suspension cannot be used interchangeably. Must be taken with high fat meal.

    POSACONAZOLE [#grey] | Noxafil
  • PRIMAQUINE
  • Primaquine Phosphate PO: malaria

    All CrCl30mgQ24H
    Hemodialysis
    Peritoneal dialysisNO DATA
    CVVH30mgQ24H

    Dose according to mg of base (30mg base = 52.6mg primaquine phosphate)

    PRIMAQUINE [#grey]
  • PYRANTEL Pin-Away, Pinworm Medicine, Antiminth, Pin-X, Ascarel, Pinworm Caplets
  • Pyrantel PO

    All CrCl11mg/kg baseQ24H
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    Max dose 1gm/day

    PYRANTEL [#grey] | Pin-Away, Pinworm Medicine, Antiminth, Pin-X, Ascarel, Pinworm Caplets
  • PYRAZINAMIDE
  • Pyrazinamide PO: tuberculosis

    CrCl ≥3025–40mg/kgQ24H
    <3025–40mg/kg3x/week
    Hemodialysis
    Peritoneal dialysis25–40mg/kgQ24H
    CVVHNO DATA

    Max dose 2gm/day; Administer post-HD on dialysis days (supplemental doses may be required if additional dialysis sessions)

    PYRAZINAMIDE [#grey]
  • PYRIMETHAMINE Daraprim, PCP, PJP
  • Pyrimethamine PO: toxoplasmosis treatment ✱ID✱

    All CrCl200mg x1, then 50–75mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Use 75mg maintenance dose if patient is >60kg

    PYRIMETHAMINE [#grey] | Daraprim, PCP, PJP
  • Pyrimethamine PO: toxoplasmosis or Pneumocystis jirovecii pneumonia prophylaxis ✱ID✱

    All CrCl50–75mgQweek
    Hemodialysis
    Peritoneal dialysis
    CVVH
    PYRIMETHAMINE [#grey] | Daraprim, PCP, PJP
  • QUININE Qualaquin, QM-260, Quinamm
  • Quinine PO: malaria, babesiosis treatment

    CrCl >50648mgQ6–8H
    10–50648mgQ8–12H
    <10648mg x1, then 324mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH648mgQ8–12H

    Dosage expressed in terms of salt. 1 capsule = 324mg of quinine sulfate = 269mg of quinine base; On dialysis days give post-HD

    QUININE [#grey] | Qualaquin, QM-260, Quinamm
  • QUINUPRISTIN-DALFOPRISTIN Synercid
  • Quinupristin-dalfopristin IV: complicated skin infections due to MRSA ✱ID✱

    All CrCl7.5mg/kgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Each 500mg vial contains 150mg of quinupristin and 350mg of dalfopristin; Not stocked, call for availability prior to ordering.

    QUINUPRISTIN-DALFOPRISTIN [#grey] | Synercid
  • Quinupristin-dalfopristin IV: bacteremia due to vancomycin-resistant E. faecium ✱ID✱

    All CrCl7.5mg/kgQ8H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Each 500mg vial contains 150mg of quinupristin and 350mg of dalfopristin; Not active against Enterococcus faecalis; Not stocked, call for availability prior to ordering.

    QUINUPRISTIN-DALFOPRISTIN [#grey] | Synercid
  • REMDESIVIR Veklury
  • Remdesivir IV: COVID-19

    All CrCl200mg x1, then 100mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    If eGFR <30 mL/min, discuss initiation with ID and/or nephrology given off-label use

    REMDESIVIR [#grey] | Veklury
  • RIFABUTIN Mycobutin
  • Rifabutin PO: treatment for tuberculosis or disseminated MAC

    All CrCl300mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Consider TDM (goal peak 0.45-0.9) and/or decrease dose if toxicity suspected. Check for drug interactions for potential dose adjustments prior to initiation

    RIFABUTIN [#grey] | Mycobutin
  • RIFAMPIN Rifadin, Rimactane
  • Rifampin PO/IV: tuberculosis ✱ID✱

    All CrCl600mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Use IV only when patient is NPO; Consider TDM in at-risk groups (diabetes, HIV, etc, goal peak 8-24)

    RIFAMPIN [#grey] | Rifadin, Rimactane
  • Rifampin PO/IV: prosthetic joint infections ✱ID✱

    All CrCl300–450mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Rifampin is generally initiated several days after other active antistaphylococcal agents have been administered

    RIFAMPIN [#grey] | Rifadin, Rimactane
  • Rifampin PO/IV: prosthetic valve endocarditis ✱ID✱

    All CrCl300mgQ8H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Rifampin is generally initiated several days after other active antistaphylococcal agents have been administered

    RIFAMPIN [#grey] | Rifadin, Rimactane
  • RIFAPENTINE Priftin
  • Rifapentine PO: tuberculosis, intensive phase ✱ID✱

    All CrCl600mgtwice a week
    Hemodialysis
    Peritoneal dialysis
    CVVH

    May consider TDM (goal peak 8-30)

    RIFAPENTINE [#grey] | Priftin
  • Rifapentine PO: tuberculosis, continuation phase ✱ID✱

    All CrCl600mgonce weekly
    Hemodialysis
    Peritoneal dialysis
    CVVH
    RIFAPENTINE [#grey] | Priftin
  • RIFAXIMIN Xifaxan
  • Rifaximin PO: recurrent Clostridioides difficile infection

    All CrCl400mgQ8H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    ID consult strongly recommended

    RIFAXIMIN [#grey] | Xifaxan
  • Rifaximin PO: hepatic encephalopathy

    All CrCl550mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    RIFAXIMIN [#grey] | Xifaxan
  • Rifaximin PO: traveler's diarrhea

    All CrCl200mgQ8H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Treatment duration is usually 3 days

    RIFAXIMIN [#grey] | Xifaxan
  • SULFADIAZENE
  • Sulfadiazine PO: Toxoplasma gondii encephalitis, acute infection

    CrCl >501000–1500mgQ6H
    10–501000–1500mgQ8–12H
    <101000–1500mgQ12–24H
    Hemodialysis1000–1500mgQ24H
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    Give with pyrimethamine and leucovorin. On dialysis days give post-HD. Use 1500mg for >60kg

    SULFADIAZENE [#grey]
  • Sulfadiazine PO: Toxoplasma gondii encephalitis, chronic maintenance therapy

    CrCl >50500–1000mgQ6H
    10–50500–1000mgQ8–12H
    <10500–1000mgQ12–24H
    Hemodialysis500–1000mgQ24H
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    Give with pyrimethamine and leucovorin. On dialysis days give post-HD

    SULFADIAZENE [#grey]
  • STREPTOMYCIN
  • Streptomycin IM/IV

    CrCl >5015mg/kgQ24H
    10–5015mg/kgQ24–72H
    <1015mg/kgQ72–96H
    Hemodialysis15mg/kgPost-HD
    Peritoneal dialysis20–40mg/L/day
    CVVH15mg/kgQ24H

    Target peak 35-45mcg/mL, goal trough <5mcg/mL; Alternative dosing for mycobacterial infections is 25mg/kg 3x/week; On dialysis days give post-HD

    STREPTOMYCIN [#grey]
  • Streptomycin IM/IV: gentamicin-resistant enterococcal endocarditis dosing

    CrCl >507.5mg/kgQ12H
    10–507.5mg/kgQ12–36H
    <107.5mg/kgQ36–48H
    Hemodialysis7.5mg/kgPost-HD
    Peritoneal dialysis20–40mg/L/day
    CVVH7.5mg/kgQ24H

    Target peak = 20-35 mcg/mL, target trough <10 mcg/mL (per 2015 AHA guidelines); On dialysis days give post-HD

    STREPTOMYCIN [#grey]
  • TEDIZOLID Sivextro
  • Tedizolid PO/IV: MRSA skin and soft tissue infection ✱ID✱

    All CrCl200mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Not recommended in neutropenic patients

    TEDIZOLID [#grey] | Sivextro
  • TELAVANCIN Vibativ
  • Telavancin IV: Serious Gram-positive infections refractory to first-line agents ✱ID✱

    CrCl >5010mg/kgQ24H
    31–507.5mg/kgQ24H
    10–3010mg/kgQ48H
    <10NO DATA
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    May interfere with coagulation assays

    TELAVANCIN [#grey] | Vibativ
  • TERBINAFINE Lamisil
  • Terbinafine PO: Fusarium, cutaneous and lymphocutaneous Sporotrichosis

    CrCl ≥50500mgQ12H
    <50NO DATA
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    Continue for 2 to 4 weeks after all lesions have healed

    TERBINAFINE [#grey] | Lamisil
  • Terbinafine PO: onychomycosis

    CrCl ≥50250mgQ24H
    <50NO DATA
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA

    6 weeks of therapy for fingernails; 12 weeks for toenails

    TERBINAFINE [#grey] | Lamisil
  • TETRACYCLINE Ala-Tet, Brodspec, Panmycin, Sumycin, Tetracap, Tetracon, Robitet 500, Emtet-500
  • Tetracycline PO

    CrCl ≥80250–500mgQ6H
    50–79250–500mgQ8H
    10–49250–500mgQ12H
    <10250–500mgQ24H
    HemodialysisNO DATA
    Peritoneal dialysisNO DATA
    CVVHNO DATA
    TETRACYCLINE [#grey] | Ala-Tet, Brodspec, Panmycin, Sumycin, Tetracap, Tetracon, Robitet 500, Emtet-500
  • TIGECYCLINE Tygacil
  • Tigecycline IV ✱ID✱

    All CrCl100mg x1, then 50mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Higher doses may be considered in certain MDR infections per IDSA guidance. Discuss with ID Pharmacy or ID for dosing recommendation

    TIGECYCLINE [#grey] | Tygacil
  • Tigecycline IV: nontuberculous mycobacterial infections ✱ID✱

    All CrCl50mgQ12–24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Consider dose escalating based on tolerance, starting with 12.5–25mg daily and increasing as tolerated

    TIGECYCLINE [#grey] | Tygacil
  • TINIDAZOLE Tindamax, Fasigyn
  • Tinidazole PO: amebiasis, bacterial vaginosis

    All CrCl2gmQ24H x2–3d
    Hemodialysis2gmSee note
    Peritoneal dialysis2gmQ24H x2–3d
    CVVH

    If administered on a day before dialysis, a dose equivalent to 1/2 the usual dose should be given post-HD

    TINIDAZOLE [#grey] | Tindamax, Fasigyn
  • Tinidazole PO: giardiasis, trichom*oniasis

    All CrCl2gmx1
    Hemodialysis
    Peritoneal dialysis
    CVVH

    On dialysis days give post-HD

    TINIDAZOLE [#grey] | Tindamax, Fasigyn
  • TOBRAMYCIN Tobramycin Sulfate ADD-Vantage
  • Tobramycin IV

    Please refer to Site-Specific Aminoglycoside Dosing Guidelines, when available.

    Please contact pharmacy department for help with monitoring serum concentrations and dosage adjustments

    TOBRAMYCIN [#grey] | Tobramycin Sulfate ADD-Vantage
  • TRIMETHOPRIM-SULFAMETHOXAZOLE Bactrim DS, Sulfatrim Pediatric, Septra, Sulfatrim, Bethaprim, Cotrim, Uroplus, Uroplus DS, Cotrim DS, Septra I.V., Bactrim I.V., Bactrim Pediatric, Bethaprim Pediatric, Sulfatrim Suspension, Cotrim Pediatric, Septra DS, SMZ-TMP, PJP, PCP, trim-sulfa, trimsulfa
  • Trimethoprim-sulfamethoxazole PO/IV: Pneumocystis jirovecii pneumonia, severe Nocardia infections, treatment dosing

    CrCl >3012–20mg/kg/dayDivided Q6–8H
    15–3012–20mg/kg/day x24h, then 6–10mg/kg/dayQ6–8H x24hr, then Q8–12H
    <155–7.5mg/kg/day divided Q12H OR 12–20mg/kg Q48H
    Hemodialysis7.5mg/kg/dayDivided Q12–24H
    Peritoneal dialysis12–20mg/kg/day x24h, then 6–10mg/kg/dayQ6–8H x24hr, then Q8–12H
    CVVHSee CVVH Dosing

    On dialysis days give post-HD; Dose always based upon trimethoprim; Indication-dependent dosing; Consider loading doses of 15mg/kg/day x24hrs for severe infection despite renal function

    TRIMETHOPRIM-SULFAMETHOXAZOLE [#grey] | Bactrim DS, Sulfatrim Pediatric, Septra, Sulfatrim, Bethaprim, Cotrim, Uroplus, Uroplus DS, Cotrim DS, Septra I.V., Bactrim I.V., Bactrim Pediatric, Bethaprim Pediatric, Sulfatrim Suspension, Cotrim Pediatric, Septra DS, SMZ-TMP, PJP, PCP, trim-sulfa, trimsulfa
  • Trimethoprim-sulfamethoxazole PO/IV: Treatment of Stenotrophom*onas maltophilia or other systemic infections

    CrCl >308–12mg/kg/dayDivided Q8–12H
    15–30Load 8–12mg/kg/day x24h, then 4–6mg/kg/doseDivided Q12H x24hr, then QD
    <154–6mg/kg/dayDivided Q12–24H
    Hemodialysis4–6mg/kg/dayQ12–24H
    Peritoneal dialysisLoad 8–12mg/kg/day x24h, then 4–6mg/kg/doseDivided Q12H x24hr, then QD
    CVVHSee CVVH Dosing

    On dialysis days give post-HD; Dose always based upon trimethoprim; Indication-dependent dosing

    TRIMETHOPRIM-SULFAMETHOXAZOLE [#grey] | Bactrim DS, Sulfatrim Pediatric, Septra, Sulfatrim, Bethaprim, Cotrim, Uroplus, Uroplus DS, Cotrim DS, Septra I.V., Bactrim I.V., Bactrim Pediatric, Bethaprim Pediatric, Sulfatrim Suspension, Cotrim Pediatric, Septra DS, SMZ-TMP, PJP, PCP, trim-sulfa, trimsulfa
  • Trimethoprim-sulfamethoxazole PO: urinary tract infections

    CrCl ≥301 DS tabletQ12H
    <301 SS tabletQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH1 DS tabletQ12H
    TRIMETHOPRIM-SULFAMETHOXAZOLE [#grey] | Bactrim DS, Sulfatrim Pediatric, Septra, Sulfatrim, Bethaprim, Cotrim, Uroplus, Uroplus DS, Cotrim DS, Septra I.V., Bactrim I.V., Bactrim Pediatric, Bethaprim Pediatric, Sulfatrim Suspension, Cotrim Pediatric, Septra DS, SMZ-TMP, PJP, PCP, trim-sulfa, trimsulfa
  • Trimethoprim-sulfamethoxazole PO: uncomplicated skin and soft tissue infections

    CrCl ≥301–2 DS tabletsQ12H
    <301 DS tabletQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH1–2 DS tabletsQ12H

    Consider 2 DS tablets in patients >100kg; On dialysis days give post-HD

    TRIMETHOPRIM-SULFAMETHOXAZOLE [#grey] | Bactrim DS, Sulfatrim Pediatric, Septra, Sulfatrim, Bethaprim, Cotrim, Uroplus, Uroplus DS, Cotrim DS, Septra I.V., Bactrim I.V., Bactrim Pediatric, Bethaprim Pediatric, Sulfatrim Suspension, Cotrim Pediatric, Septra DS, SMZ-TMP, PJP, PCP, trim-sulfa, trimsulfa
  • Trimethoprim-sulfamethoxazole PO: lung transplant or HIV-infected Pneumocystis jirovecii pneumonia prophylaxis

    CrCl ≥301 DS tablet TIW or Q24H, OR 1 SS tablet Q24H
    <301 SS tabletTIW
    Hemodialysis1 DS tabletTIW
    Peritoneal dialysis1 SS tabletTIW
    CVVH1 DS tablet TIW OR 1 SS tablet Q24H

    On dialysis days give post-HD; TIW = 3x weekly; Lung transplant: continue indefinitely after transplant, defer to institutional guidelines

    TRIMETHOPRIM-SULFAMETHOXAZOLE [#grey] | Bactrim DS, Sulfatrim Pediatric, Septra, Sulfatrim, Bethaprim, Cotrim, Uroplus, Uroplus DS, Cotrim DS, Septra I.V., Bactrim I.V., Bactrim Pediatric, Bethaprim Pediatric, Sulfatrim Suspension, Cotrim Pediatric, Septra DS, SMZ-TMP, PJP, PCP, trim-sulfa, trimsulfa
  • Trimethoprim-sulfamethoxazole PO: renal transplant Pneumocystis jirovecii pneumonia prophylaxis

    CrCl ≥501 SS tabletQ24H
    <501 SS tabletQ48H
    Hemodialysis1 SS tablet2x weekly
    Peritoneal dialysis1 SS tabletQ48H
    CVVH1 SS tablet2x weekly

    Pneumocystis jirovecii pneumonia prophylaxis will continue for 12 months after renal transplant, defer to institutional guidelines

    TRIMETHOPRIM-SULFAMETHOXAZOLE [#grey] | Bactrim DS, Sulfatrim Pediatric, Septra, Sulfatrim, Bethaprim, Cotrim, Uroplus, Uroplus DS, Cotrim DS, Septra I.V., Bactrim I.V., Bactrim Pediatric, Bethaprim Pediatric, Sulfatrim Suspension, Cotrim Pediatric, Septra DS, SMZ-TMP, PJP, PCP, trim-sulfa, trimsulfa
  • VALACYCLOVIR Valtrex
  • Valacyclovir PO: Zoster/HSV treatment

    CrCl ≥501000mgQ8H
    30–491000mgQ12H
    10–291000mgQ24H
    <10500mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    On dialysis days, give post-HD

    VALACYCLOVIR [#grey] | Valtrex
  • Valacyclovir PO: prophylaxis/suppression, including lung transplant prophylaxis

    CrCl ≥30500mgQ12H
    <30500mgQ24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Lung transplant: prophylaxis will continue for 3 months post transplant, defer to institutional guidelines; on dialysis days give post-HD

    VALACYCLOVIR [#grey] | Valtrex
  • Valacyclovir PO: Renal Transplant prophylaxis

    CrCl ≥501000mgQ24H
    <501000mgQ48H
    Hemodialysis500mgQ24H
    Peritoneal dialysis
    CVVH

    Used in renal transplant recipients for 6 months post transplant; on dialysis days give post-HD

    VALACYCLOVIR [#grey] | Valtrex
  • VALGANCICLOVIR Valcyte
  • Valganciclovir PO: Renal transplant prophylaxis

    CrCl ≥40450mgQ24H
    25–39450mgQ48H
    10–24450mg2x/week
    <10
    Hemodialysis450mgPost-HD
    Peritoneal dialysis450mg2x/week
    CVVH450mgQ48H

    Prophylaxis will continue for 6 months post renal transplant

    VALGANCICLOVIR [#grey] | Valcyte
  • Valganciclovir PO: maintenance/suppression/prophylaxis

    CrCl ≥60900mgQ24H
    40–59450mgQ24H
    25–39450mgQ48H
    <25450mg2x/week
    Hemodialysis450mgPost-HD
    Peritoneal dialysisAVOID –NO DATA
    CVVH450mgQ48H

    Please Refer to the BWH or MGH Lung Transplant Manual for prophylactic dosing

    VALGANCICLOVIR [#grey] | Valcyte
  • Valganciclovir PO: CMV treatment

    CrCl ≥60900mgQ12H
    40–59450mgQ12H
    25–39450mgQ24H
    <25450mgQ48H
    Hemodialysis450mgPost-HD
    Peritoneal dialysisUse IV ganciclovir for induction
    CVVHUse IV ganciclovir for induction
    VALGANCICLOVIR [#grey] | Valcyte
  • VANCOMYCIN Firvanq
  • Vancomycin IV: systemic infections

    MGB Guidance and MGH-specific guidance

    Please contact the pharmacy department for help with monitoring serum concentrations and dosage adjustments; Round all doses to nearest 250 mg

    VANCOMYCIN [#grey] | Firvanq
  • Vancomycin PO: Clostridioides difficile treatment ONLY

    All CrCl125mgQ6H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    500mg may be used in select fulminant C. difficile cases; also refer to C. diff treatment guideline

    VANCOMYCIN [#grey] | Firvanq
  • Vancomycin PO: Clostridioides difficile prophylaxis ONLY

    All CrCl125mgQ12–24H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Data on the use of oral vancomycin for C. difficile prophylaxis is conflicting

    VANCOMYCIN [#grey] | Firvanq
  • VORICONAZOLE VFEND
  • Voriconazole PO ✱ID✱

    All CrCl400mg Q12H x2, then 200–300mgQ12H
    Hemodialysis
    Peritoneal dialysis
    CVVH

    Suggested therapeutic range 1.5–5 mcg/mL. If level is subtherapeutic, can consider increasing frequency to q8h. Please refer to local guidelines for specific dose adjustments

    VORICONAZOLE [#grey] | VFEND
  • Voriconazole IV ✱ID✱

    CrCl ≥506mg/kg Q12H x2, then 4mg/kgQ12H
    HemodialysisIV not recommended, however clinical situations may warrant therapy; consult ID
    Peritoneal dialysisIV not recommended, however clinical situations may warrant therapy; consult ID
    CVVHIV not recommended, however clinical situations may warrant therapy; consult ID

    Suggested therapeutic range 1.5-5 mcg/mL; Switch to PO when stable or CrCl < 50. Please refer to local guidelines for specific dose adjustments

    VORICONAZOLE [#grey] | VFEND
  • ZANAMIVIR Relenza
  • Zanamivir Inhalation: influenza treatment ✱ID✱

    All CrCl10mg (2 inhalations)Q12H
    Hemodialysis
    Peritoneal dialysis
    CVVH
    ZANAMIVIR [#grey] | Relenza
  • ABOUT THIS PAGE
  • created by Theodore Pak (tpak [at] mgh)
  • White Book - MGB Antimicrobial Dosing June 2023 (2024)

    FAQs

    What are the treatment guidelines for CRE? ›

    Question 1: What Are Preferred Antibiotics for the Treatment of Uncomplicated Cystitis Caused by CRE? Recommendation: Ciprofloxacin, levofloxacin, trimethoprim-sulfamethoxazole, nitrofurantoin, or a single-dose of an aminoglycoside are preferred treatment options for uncomplicated cystitis caused by CRE.

    How do you treat NDM E coli? ›

    Most NDM-1 strains must be treated with an older antibiotic called colistin, which had fallen out of use because it can be toxic to kidneys. Some strains may be treatable with the antibiotic aztreonam, or a newer one, tigecycline (Tygacil).

    What is the drug of choice for carbapenem resistance? ›

    carbapenem resistant Enterobacterales

    Therefore, aztreonam is a prudent choice for combating MBL-producing organisms, despite the fact that it can be hydrolyzed by extended-spectrum -lactamases (ESBLs) or Ambler class C -lactamases, both of which are co-produced in MBL-producing organisms.

    How do I permanently get rid of E. coli? ›

    There is no specific treatment for E. coli O157 infection. People who are infected can usually be cared for at home and most will get better without medical treatment. It's important to drink plenty of fluids, as diarrhoea can lead to dehydration.

    How do you treat NDM positive? ›

    Treatment of NDM producers is an unmet need. Ceftazidime-avibactam and aztreonam combination or cefiderocol can be used for NDM producers, where available. Higher cefiderocol MICs against NDM producers is concerning. Aztreonam-avibactam provides hope for the treatment of NDM producers.

    What antibiotics are used to treat NDM Klebsiella? ›

    Ceftazidime-avibactam is recommended as the first-line therapeutic agent for OXA-48 producers. Ceftazidime-avibactam plus aztreonam and cefiderocol are the first-line options for NDM-CRKP infections. Colistin- or tigecycline-based regimens may be considered as alternatives if newer antibiotics cannot be used.

    What are the new treatment guidelines for Clostridium difficile? ›

    2021 Updated ISDA/SHEA guidelines

    In patients with a first CDI episode, fidaxomicin is recommended instead of a standard course of vancomycin. In those with recurrent CDI episodes, fidaxomicin (standard or extended-pulsed regimen), rather than a standard course of vancomycin, is recommended.

    What precautions should be taken for carbapenem-resistant Enterobacteriaceae? ›

    Remind family and friends to wash their hands when entering and leaving your room and before and after touching you. Never touch other people's cuts, sores, or rashes unless you are wearing gloves. If you need to stay in a healthcare facility in the future, you should tell healthcare staff about your CRE status.

    What infection control precautions would you use for a patient with confirmed CPE? ›

    In isolation rooms

    Visitors must not use patient bathrooms. Patients must wash their hands well, with soap and water, before eating meals and after going to the toilet. Patients should avoid touching medical devices (if they have any) such as urinary catheter tubes and intravenous drips, particularly at the entry site.

    Top Articles
    Latest Posts
    Article information

    Author: Arline Emard IV

    Last Updated:

    Views: 5554

    Rating: 4.1 / 5 (52 voted)

    Reviews: 91% of readers found this page helpful

    Author information

    Name: Arline Emard IV

    Birthday: 1996-07-10

    Address: 8912 Hintz Shore, West Louie, AZ 69363-0747

    Phone: +13454700762376

    Job: Administration Technician

    Hobby: Paintball, Horseback riding, Cycling, Running, Macrame, Playing musical instruments, Soapmaking

    Introduction: My name is Arline Emard IV, I am a cheerful, gorgeous, colorful, joyous, excited, super, inquisitive person who loves writing and wants to share my knowledge and understanding with you.